RespireRx Pharmaceuticals (RSPI) 10-Q 17 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	1-16467
Entity Registrant Name	RESPIRERX PHARMACEUTICALS INC.
Entity Central Index Key	0000849636
Entity Tax Identification Number	33-0303583
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	126 Valley Road
Entity Address, Address Line Two	Suite C
Entity Address, City or Town	Glen Rock
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07452
City Area Code	(917)
Local Phone Number	834-7206
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		365,418,647

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,362	$ 88
Deferred financing costs	6,457
Prepaid research and development	48,568
Prepaid expenses	47,277	22,693
Total current assets	108,664	22,781
Total assets	108,664	22,781
Current liabilities:
Accounts payable and accrued expenses, including amounts owed to related parties (Note 5)	6,627,788	5,724,390
Accrued compensation and related expenses	2,652,336	3,296,008
Convertible notes payable, currently due and payable on demand, including accrued interest of $387,032 and $327,881 at September 30, 2023 and December 31, 2022, respectively (Note 4)	1,215,088	1,258,315
Other short-term notes payable	26,311	15,847
Total current liabilities	12,061,118	11,729,101
Long-term liabilities
Long-term accounts payable associated with payment settlement agreements, all long-term at September 30, 2023 and net of current portion included in accounts payable at December 31, 2022 (Note 5)	344,000	174,000
Total long-term liabilities	344,000	174,000
Total liabilities	12,405,118	11,903,101
Commitments and contingencies (Note 8)
Stockholders’ deficiency: (Note 6)
Common stock, $0.001 par value; shares authorized: 2,000,000,000; shares issued and outstanding: 298,328,647 outstanding at September 30, 2023 and 125,544,276 at December 31, 2022, respectively	298,329	125,544
Additional paid-in capital	164,158,537	164,030,289
Accumulated deficit	(177,564,451)	(176,057,856)
Total stockholders’ deficiency	(12,296,454)	(11,880,320)
Total liabilities and stockholders’ deficiency	108,664	22,781
Series B Convertible Preferred Stock [Member]
Stockholders’ deficiency: (Note 6)
Preferred stock, value	21,703	21,703
Series I 8% Redeemable Preferred Stock [Member]
Stockholders’ deficiency: (Note 6)
Preferred stock, value	173,037
Series J 8% Redeemable Preferred Stock [Member]
Stockholders’ deficiency: (Note 6)
Preferred stock, value	616,391
SY Corporation [Member]
Current liabilities:
Notes payable	809,625	833,463
Officer [Member]
Current liabilities:
Notes payable	487,342	375,334
Former Officer [Member]
Current liabilities:
Notes payable	$ 242,628	$ 225,744

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	298,328,647	125,544,276
Common stock, shares outstanding	298,328,647	125,544,276
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference per share	$ 0.6667	$ 0.6667
Preferred stock, aggregate liquidation preference value	$ 25,001	$ 25,001
Preferred stock, shares authorized	37,500	37,500
Preferred stock, shares issued	37,500	37,500
Preferred stock, shares outstanding	37,500	37,500
Preferred stock, conversion price	$ 0.000030	$ 0.000030
Series I 8% Redeemable Preferred Stock [Member]
Preferred stock, par value	0.001	0.001
Preferred stock, liquidation preference per share	$ 100	$ 100
Preferred stock, shares authorized	3,500	3,500
Preferred stock, shares issued	1,730	1,730
Preferred stock, shares outstanding	1,730	1,730
Series J 8% Redeemable Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference per share	$ 100	$ 100
Preferred stock, shares authorized	15,000	15,000
Preferred stock, shares issued	6,164	6,164
Preferred stock, shares outstanding	6,164	6,164
SY Corporation [Member]
Accrued interest	$ 543,343	$ 507,330
Convertible Notes Payable [Member]
Accrued interest	$ 387,032	$ 327,881

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
General and administrative, including related parties	$ 245,129	$ 250,916	$ 902,866	$ 958,086
Research and development, including related parties	87,380	138,050	284,020	400,307
Total operating expenses	332,509	388,966	1,186,886	1,358,393
Loss from operations	(332,509)	(388,966)	(1,186,886)	(1,358,393)
Loss on extinguishment or settlement or modification of debt and other liabilities		(71,161)		(71,161)
Interest expense, including related parties	(73,408)	(94,643)	(365,729)	(533,812)
Foreign currency transaction gain	10,415	82,192	46,020	150,337
Net loss	(395,502)	(472,578)	(1,506,595)	(1,813,029)
Deemed dividend associated with paid-in-kind dividends on preferred stock for the three-months and nine-months periods ending September 30, 2023 and most favored nation provisions of convertible notes for the three-months and nine-months periods ending September 30, 2022	(13,667)	(1,168,594)	(24,427)	(1,520,332)
Net loss attributable to common stockholders	$ (409,169)	$ (1,641,172)	$ (1,531,022)	$ (3,333,361)
Net loss per common share attributable to common stockholders - basic	$ (0.002)	$ (0.014)	$ (0.008)	$ (0.031)
Net loss per common share attributable to common stockholders - diluted	$ (0.002)	$ (0.014)	$ (0.008)	$ (0.031)
Weighted average common shares outstanding - basic	267,732,995	119,264,928	191,241,348	107,816,034
Weighted average common shares outstanding - diluted	267,732,995	119,264,928	191,241,348	107,816,034

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Balance	$ (12,142,352)	$ (12,310,383)	$ (11,880,320)	$ (11,131,459)	$ (10,867,921)	$ (10,007,758)	$ (11,880,320)	$ (10,007,758)
Issuance of common stock upon cashless exercise of warrants
Warrant value for issuance of convertible note					25,000
Net loss	(395,502)	(681,030)	(430,063)	(472,578)	(480,288)	(860,163)	(1,506,595)	(1,813,029)
Issuance of Series I Preferred Stock	100,000	70,000
Accrued dividends on Series I Preferred Stock
Issuance of Series J Preferred Stock	25,000	570,000
Accrued dividends on Series J Preferred Stock
Issuance of common stock upon convertible note conversion	116,400	84,061		25,250	191,750
Warrant issuances with respect to Demand Promissory Notes		125,000
Balance	(12,296,454)	(12,142,352)	(12,310,383)	(11,590,629)	(11,131,459)	(10,867,921)	(12,296,454)	(11,590,629)
Issuance of convertible notes				(11,842)
Preferred Stock [Member] | Series B Convertible Preferred Stock [Member]
Balance	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703
Balance, shares	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500
Issuance of common stock upon cashless exercise of warrants
Warrant value for issuance of convertible note
Net loss
Issuance of Series I Preferred Stock
Accrued dividends on Series I Preferred Stock
Issuance of Series J Preferred Stock
Accrued dividends on Series J Preferred Stock
Issuance of common stock upon convertible note conversion
Warrant issuances with respect to Demand Promissory Notes
Balance	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703
Balance, shares	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500
Issuance of convertible notes
Preferred Stock [Member] | Series I 8% Redeemable Preferred Stock [Member]
Balance	$ 70,891
Balance, shares	709
Issuance of common stock upon cashless exercise of warrants
Warrant value for issuance of convertible note
Net loss
Issuance of Series I Preferred Stock	$ 100,000	$ 70,000
Issuance of Series I Preferred Stock, shares	1,000	700
Accrued dividends on Series I Preferred Stock	$ 2,146	$ 891
Accrued dividends on Series I Preferred Stock shares	21	9
Issuance of Series J Preferred Stock
Accrued dividends on Series J Preferred Stock
Issuance of common stock upon convertible note conversion
Warrant issuances with respect to Demand Promissory Notes
Balance	$ 173,037	$ 70,891					$ 173,037
Balance, shares	1,730	709					1,730
Issuance of convertible notes
Preferred Stock [Member] | Series J 8% Redeemable Preferred Stock [Member]
Balance	$ 579,870
Balance, shares	5,799
Issuance of common stock upon cashless exercise of warrants
Warrant value for issuance of convertible note
Net loss
Issuance of Series I Preferred Stock
Accrued dividends on Series I Preferred Stock
Issuance of Series J Preferred Stock	$ 25,000	$ 570,000
Issuance of Series J Preferred Stock, shares	250	5,700
Accrued dividends on Series J Preferred Stock	$ 11,521	$ 9,870
Accrued dividends on Series J Preferred Stock shares	115	99
Issuance of common stock upon convertible note conversion
Warrant issuances with respect to Demand Promissory Notes
Balance	$ 616,391	$ 579,870					$ 616,391
Balance, shares	6,164	5,799					6,164
Issuance of convertible notes
Common Stock [Member]
Balance	$ 220,729	$ 144,327	$ 125,544	$ 117,069	$ 97,894	$ 97,894	$ 125,544	$ 97,894
Balance, shares	220,728,647	144,326,672	125,544,276	117,069,276	97,894,276	97,894,276	125,544,276	97,894,276
Issuance of common stock upon cashless exercise of warrants		$ 20,362	$ 18,783
Issuance of common stock upon cashless warrant exercise, shares	77,600,000	20,361,976	18,782,396
Warrant value for issuance of convertible note
Net loss
Issuance of Series I Preferred Stock
Accrued dividends on Series I Preferred Stock
Issuance of Series J Preferred Stock
Accrued dividends on Series J Preferred Stock
Issuance of common stock upon convertible note conversion	77,600	$ 56,040		$ 2,525	$ 19,175
Issuance of common stock upon convertible note conversion, shares		56,039,999		2,525,000	19,175,000
Warrant issuances with respect to Demand Promissory Notes
Balance	$ 298,329	$ 220,729	$ 144,327	$ 119,594	$ 117,069	$ 97,894	$ 298,329	$ 119,594
Balance, shares	298,328,647	220,728,647	144,326,672	119,594,276	117,069,276	97,894,276	298,328,647	119,594,276
Issuance of convertible notes
Additional Paid-in Capital [Member]
Balance	$ 164,133,404	$ 164,011,506	$ 164,030,289	164,025,356	$ 163,827,781	$ 163,827,781	$ 164,030,289	$ 163,827,781
Issuance of common stock upon cashless exercise of warrants		(20,362)	(18,783)
Warrant value for issuance of convertible note					25,000
Net loss
Issuance of Series I Preferred Stock
Accrued dividends on Series I Preferred Stock	(2,146)	(891)
Issuance of Series J Preferred Stock
Accrued dividends on Series J Preferred Stock	(11,521)	(9,870)
Issuance of common stock upon convertible note conversion	38,800	28,021		22,725	172,575
Warrant issuances with respect to Demand Promissory Notes		125,000
Balance	164,158,537	164,133,404	164,011,506	164,036,239	164,025,356	163,827,781	164,158,537	164,036,239
Issuance of convertible notes				(11,842)
Retained Earnings [Member]
Balance	(177,168,949)	(176,487,919)	(176,057,856)	(175,295,587)	(174,815,299)	(173,955,136)	(176,057,856)	(173,955,136)
Issuance of common stock upon cashless exercise of warrants
Warrant value for issuance of convertible note
Net loss	(395,502)	(681,030)	(430,063)	(472,578)	(480,288)	(860,163)
Issuance of Series I Preferred Stock
Accrued dividends on Series I Preferred Stock
Issuance of Series J Preferred Stock
Accrued dividends on Series J Preferred Stock
Issuance of common stock upon convertible note conversion
Warrant issuances with respect to Demand Promissory Notes
Balance	$ (177,564,451)	$ (177,168,949)	$ (176,487,919)	(175,768,165)	$ (175,295,587)	$ (174,815,299)	$ (177,564,451)	$ (175,768,165)
Issuance of convertible notes

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (395,502)	$ (430,063)	$ (472,578)	$ (860,163)	$ (1,506,595)	$ (1,813,029)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of original issue discount, capitalized note costs and debt discounts to interest expense					136,077	382,377
Stock-based compensation included in -
Loss on modification of convertible notes						71,161
Foreign currency transaction (gain) loss					(46,020)	(150,337)
Increase (decrease) in cash from
Deferred financing costs					6,457	177,883
Prepaid expenses and prepaid research and development					73,152	74,764
Fees paid with shares of Common Stock
Accounts payable and accrued expenses					801,167	438,950
Accrued compensation and related expenses					(433,672)	522,000
Officer and affiliate liabilities, including accrued interest					311,081
Accrued interest payable and notes payable					399,627	139,170
Net cash used in operating activities					(258,726)	(155,061)	$ (143,905)
Cash flows from financing activities:
Proceeds from convertible note borrowings						120,000
Proceeds from sale of preferred stock					170,000
Proceeds from demand promissory notes					95,000
Borrowings on short-term notes payable, net of repayments						(75,689)
Proceeds from or repayment of officer advance						109,412
Net cash provided by financing activities					265,000	153,723
Cash and cash equivalents:
Net (decrease)/increase					6,274	(1,338)
Balance at beginning of period		$ 88		$ 1,398	88	1,398	1,398
Balance at end of period	$ 6,362		$ 60		6,362	60	$ 88
Cash paid for -
Interest					8,222	10,308
Income taxes
Non-cash financing activities:
Reclassification of short-term liabilities to long-term liabilities					270,000
Reclassification of long-term liabilities to short-term liabilities						90,000
Insurance policies					96,470	95,850
Conversion of accounts payable to officer to notes payable to officer						13,659
Commitment shares/warrants issued with debt financing						13,158
Shares issued with conversion of debt					200,460	217,000
Accrued compensation, accounts payable and other liabilities exchanged or settled for equity					620,000
Issuance of warrants as deemed dividends associated with most-favored nation provisions of convertible notes						1,623,054
Issuance of preferred stock as deemed dividends associated with paid-in-kind dividends on Series I and Series J preferred stock					24,427
Debt discounts established for convertible debt						13,334
Cashless warrant exercises					39,145
Equity Based Conversion Fees [Member]
Stock-based compensation included in -
Share-based payment arrangement, expense						$ 2,000

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Organization RespireRx Pharmaceuticals Inc. (“RespireRx”) was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. Currently RespireRx and its subsidiaries are focusing and emphasizing their historical efforts on data mining, re-discovery and re-purposing of known drugs and drug candidates to reduce risks and costs associated with drug development. On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. In August 2012, RespireRx acquired Pier Pharmaceuticals, Inc. (“Pier”), which is now a wholly-owned subsidiary. Pier was a clinical stage biopharmaceutical company developing a pharmacologic treatment for obstructive sleep apnea (“OSA”) and had been engaged in research and clinical development activities which activities are now in RespireRx’s wholly-owned subsidiary ResolutionRx Ltd (“ResolutionRx”). Pier is currently inactive. On January 11, 2023, RespireRx formed as a wholly-owned subsidiary, ResolutionRx, an unlisted public company in Australia, into which RespireRx, as of August 3, 2023, has contributed its cannabinoid platform described below. Basis of Presentation The condensed consolidated financial statements are of RespireRx and its wholly-owned subsidiaries, Pier and ResolutionRx (collectively referred to herein, along with its business unit, EndeavourRx, as the “Company,” the “RespireRx Group”, “we” or “our,” unless the context indicates otherwise). The condensed consolidated financial statements and related notes are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and other information included in the Company’s Annual Report in our Form 10-K for the fiscal year ended December 31, 2022 as filed with the SEC on April 17, 2023 (“2022 Form 10-K”).

Business

Business	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Business	2. Business Mission The mission of the RespireRx Group, is to develop innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling at reduced risk and cost. In pursuit of this goal, we have (i) used data mining to identify and acquire new GABAkines, a family of compounds that have displayed a high degree of efficacy in a wide range of animal studies and are undergoing preclinical safety studies; (ii) re-discovered the safety of our low impact AMPAkines, a class of compounds that have been under- or unrecognized, and have advanced their clinical development and (iii) have re-purposed dronabinol, an already approved drug, and developed it forward into late stage clinical status for use as a new proprietary treatment. We have focused on treatment options that address conditions affecting millions of people, but for which there are limited or poor treatment options, including OSA, attention deficit hyperactivity disorder (“ADHD”), epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, recovery from spinal cord injury (“SCI”) and certain orphan disorders. As we move forward, we may also consider developing treatment options for other conditions based on results of preclinical and clinical studies to date. To achieve these goals, the Company has determined that some or all of these opportunities should be licensed, sub-licensed, joint ventured or even sold and has initiated efforts to do so. Strategy It is generally agreed that drug research and development (“R&D”) programs can cost hundreds of millions of dollars, take years if not decades to complete and carry considerable risk to successfully complete. While large, well-funded companies can undertake such ventures, smaller companies must seek out other creative and disruptive approaches to compete in the drug discovery and development process. We believe we have identified three basic methods that, when utilized, allow us to reduce risk, minimize costs and create considerable value. Data-mining Re-Discovery Re-Purposing Implementation In order to facilitate our business activities and product development and to set up our programs for partnering or sale, the Company has implemented an internal restructuring plan based upon our two research platforms: drugs that act directly upon endocannabinoid receptors and drugs that act as neuromodulators at AMPA glutamate and GABA A (i) ResolutionRx, our repurposing platform is developing dronabinol initially for the treatment of OSA and later for other indications. Dronabinol is already approved by the U.S. FDA and other national regulatory agencies for other indications, allowing for a more rapid route to approval. (ii) EndeavourRx, our neuromodulators rediscovery platform is made up of two programs: (a) our AMPAkines program, which is developing proprietary compounds that act as positive allosteric modulators (“PAMs”) of AMPA-type glutamate receptors to promote neuronal function and (b) our GABAkines program, which is developing proprietary compounds that act as PAMs of GABA A ResolutionRx, was organized January 11, 2023 as a wholly-owned subsidiary of RespireRx. We are also evaluating whether to organize our EndeavourRx business unit, in part or in whole, into one or more subsidiaries that would conduct R&D of our neuromodulator platform, including either or both of the AMPAkine and GABAkine programs and their related tangible and intangible assets and certain of their liabilities. The RespireRx Group, comprised of RespireRx, ResolutionRx and EndeavourRx (and Pier, which is inactive), believes that there are advantages to separating these platforms formally into newly formed subsidiaries, including but not limited to optimizing their asset values by making them attractive to separate financing and strategic partnering channels. The Company’s business development efforts (licensing, sub-licensing, joint venture and other commercial structures), if successful, would represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. These efforts have focused on, but have not been limited to, transacting with brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful clinical development, formulation or manufacturing capabilities, significant subject matter expertise and financial resources. No assurance can be given that any transaction will come to fruition and that, if it does, the terms will be favorable to the Company. Financing our Platforms Our major challenge has been to raise substantial equity or equity-linked financing to support research and development plans for our cannabinoid and neuromodulator platforms, while minimizing the dilutive effect to pre-existing stockholders. At present, we believe that we are hindered primarily by our public corporate structure, our OTC Pink Market listing and our low market capitalization as a result of our low stock price as well as the weakness of our balance sheet. For this reason, the Company has affected an internal restructuring plan described above that we believe will further the aims of RespireRx, ResolutionRx and EndeavourRx, and may make it possible, through separate finance channels, to unlock the unrealized asset values of each and set up its programs for partnering or sale. We believe that some or all of our assets should be licensed, sub-licensed, joint ventured or even sold and have initiated efforts to do so. No assurance can be given that any transaction will come to fruition and that if it does, that the terms will be favorable to the Company. ResolutionRx is eligible to participate in the Australian R&D Tax Incentive (“R&DTI”), which is a tax rebate by the Australian government for qualified R&D expenditures. In the case of ResolutionRx, the R&DTI is expected to be 43.5% of qualified R&D. On January 27, 2023, ResolutionRx entered into a Letter of Intent and a term sheet with Radium Capital pursuant to which Radium Capital will finance in accordance with a debt facility, 80% or ResolutionRx’s of 43.5% tax rebate on an ongoing application basis similar to a line of credit. On May 18, 2023, ResolutionRx entered into a Letter of Intent with Cantheon Capital (“Cantheon” and “Cantheon LOI”) that describes an intended investment of US$3, 125,000 25 On May 11, 2023, RespireRx entered into a Letter Agreement (“Letter Agreement”) with Viridian Capital Advisors (“VCA”) pursuant to which, VCA would perform the following services (“Valuation Services”): (i) review the Company’s intellectual property assets and licensing agreements as they relate to Company’s cannabinoid program, net of any associated liabilities, (ii) review the Company’s financial models and forecasts as they relate to the Company’s cannabinoid program and (iii) prepare the data, analytics and Company valuation analysis (“Valuation Analysis”) specifically with respect to the Company’s cannabinoid program. The Letter Agreement became effective on May 22, 2023. The Company entered this Letter Agreement as part of the process that began with the establishment of ResolutionRx, into which the net assets of the Company’s cannabinoid program have been contributed via license and sublicense in exchange for 25,000,000 On February 27, 2023, ResolutionRx entered into a Services Agreement with iNGENu CRO Pty Ltd - See Note 8. Commitments and Contingencies- Significant Agreements and Contracts – On August 3, 2023, RespireRx entered into a License Agreement with ResolutionRx - See Note 8. Commitments and Contingencies - Significant Agreements and Contracts - License Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx entered into a Sublicense Agreement with ResolutionRx - See Note 8. Commitments and Contingencies - Significant Agreements and Contracts - On August 3, 2023, RespireRx entered into a Stock Transfer Agreement with ResolutionRx - See Note 8. Commitments and Contingencies - Significant Agreements and Contracts - On August 3, 2023, RespireRx entered into a Master Intercompany Services Agreement with ResolutionRx – See Note 8. Commitments and Contingencies – Significant Agreements and Contracts On October 9, 2023, ResolutionRx entered into a Master Services Agreement (“MSA”) with Ab Initio Pharma Pty Ltd, (“Ab Initio”) an Australian company under which Ab Initio will manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx - See Note 8. Commitments and Contingencies - Significant Agreements and Contracts – Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses and net losses attributable to common stockholders of $ 395,502 409,169 1,506,595 1,531,022 472,578 1,813,029 1,641,172 3,333,361 3,972,993 258,726 143,905 12,296,454 1,215,088 The Company is currently, and has for some time, been in significant financial distress. It has extremely limited cash resources and current assets and has no ongoing source of sustainable revenue. Management is continuing to address various aspects of the Company’s operations and obligations, including, without limitation, debt obligations, financing requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance, and has taken steps to continue to raise new debt and equity capital to fund the Company’s business activities from both related and unrelated parties. The Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its business activities on a going forward basis, including the pursuit of the Company’s planned research and development activities. Such activities have commenced with iNGENu with ResolutionRx and certain R&D activities are taking place at collaborating academic institutions. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including development and other agreements with collaborative partners and, when necessary, seeking to exchange or restructure the Company’s outstanding securities and liabilities. The Company is evaluating certain changes to its operations and structure to facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s development programs and, in that regard, has formed an Australian subsidiary, ResolutionRx. In addition to the formation of ResolutionRx, such changes could include additional significant reorganizations, which may include the formation of one or more additional subsidiaries into which one or more programs may be contributed. As a result of the Company’s current financial situation, the Company has limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate. As an example of its efforts to address outstanding accounts payable, on September 26, 2023, the Company entered into a Second Amendment to Consulting Agreement and a Settlement and Exchange Agreement with DNA Healthlink Inc. pursuant which $ 50,000 25,000 25,000 The Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its business activities on a going forward basis, including the pursuit of the Company’s planned R&D activities. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including development and other agreements with collaborative partners and, when necessary, seeking to exchange or restructure the Company’s outstanding securities. The Company is evaluating certain changes to its operations and structure to facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s development programs. In addition to the formation of ResolutionRx, such changes could include additional significant reorganizations, which may include the formation of one or more additional subsidiaries into which one or more programs may be contributed. As a result of the Company’s current financial situation, the Company has limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements (unaudited) are prepared in accordance with GAAP and include the financial statements of RespireRx and its wholly-owned subsidiaries, Pier and ResolutionRx. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. Value of Financial Instruments The authoritative guidance with respect to value of financial instruments established a value hierarchy that prioritizes the inputs to valuation techniques used to measure value into three levels and requires that assets and liabilities carried at value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the value hierarchy within which each value measurement falls in its entirety, based on the lowest level input that is significant to the value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, and accounts payable and accrued expenses) are considered by the Company to be representative of the respective values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date for companies like the Company. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective values of such instruments due to the short-term nature of those instruments and their terms. Capitalized Financing Costs The Company presents debt issuance costs related to debt obligations in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt obligation, consistent with the presentation for debt discounts. Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants, commitment shares of Common Stock, the convertible notes and equity or equity-linked securities are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued in connection with and at the time of such financing. Debt and Other Liability Exchanges In cases where debt or other liabilities are exchanged for equity, the Company compares the carrying value of debt, inclusive of accrued interest, if applicable, being exchanged, to the fair value of the equity issued and records any loss or gain as a result of such exchange. See Note 4. Notes Payable. Extinguishment of Debt and Settlement of Liabilities The Company accounts for the extinguishment of debt and settlement of liabilities by comparing the carrying value of the debt or liability to the value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. Prepaid Insurance Prepaid insurance represents the premium that was due in March 2023 for directors and officers insurance. The amounts of prepaid insurance amortizable in the ensuing twelve-month period are recorded as prepaid insurance in the Company’s consolidated balance sheet at each reporting date and amortized to the Company’s consolidated statement of operations for each reporting period. Stock-Based Awards The Company periodically issues common stock, stock options and phantom stock (collectively, “Stock-Based Awards”) to officers, directors, Scientific Advisory Board members, consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated or condensed consolidated financial statements over the vesting period of the awards. Stock grants, which are sometimes subject to time-based vesting, are measured at the grant date fair value of the common stock and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s outside consultants and other vendors are valued on the grant date. As the stock options vest, the Company recognizes this expense over the period in which the services are provided. The value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock and stock option grants and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. Phantom stock awards, which are sometimes subject to time-based vesting, are measured at the award date fair value, if measurable. As the phantom stock awards vest, the Company recognizes the expense, if measurable, upon vesting. To the extent that the value of phantom stock awards is not measurable on the award date, measurement only being possible on the satisfaction of certain contingent events that may not be predictable and measurable at the time of the award, the Company recognizes the expense as a change in an estimate as of the date on which the contingent event becomes predictable and measurable. The Company recognizes the value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated or condensed consolidated statements of operations, as appropriate. The Company issues new shares of Common Stock to satisfy stock option and warrant exercises. There were no There were no There were no 83,333,333 250,000 Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, management does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2023, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2023 and December 31, 2022, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The accounts for ResolutionRx are maintained in Australian dollars and are converted to U.S. dollars at the exchange rate on the balance sheet. In both cases, the foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations. Research and Development Research and development costs include compensation paid to management directing the Company’s R&D activities, including but not limited to compensation paid to our Chief Scientific Officer who is also our Executive Chairman, Interim President and Interim Chief Executive Officer, and who has similar roles at ResolutionRx, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, research, development and clinical testing of the Company’s treatments and product candidates. License Agreements Obligations incurred with respect to mandatory payments provided for in-license agreements are recognized ratably over the appropriate term, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in-license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development expenses in the Company’s condensed consolidated statement of operations. Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses. Earnings (Loss) per Share The Company’s computation of earnings (loss) per common share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net loss attributable to common stockholders consists of net loss, as adjusted for actual and deemed stock dividends declared, accrued, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2023 and 2022 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 September 30, 2023 2022 Series B convertible preferred stock 1 1 Convertible notes payable 652,721,528 348,938,988 Common stock warrants 395,515,209 245,030,149 Common stock options 9,168,317 9,201,032 Total 1,057,405,055 603,170,170 Reclassifications Certain comparative figures in 2022 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Notes Payable	4. Notes Payable Convertible Notes Payable The table below summarizes all convertible notes outstanding as of September 30, 2023. Those with similar characteristics outstanding as of September 30, 2023 are grouped separately. The following abbreviations are used in the column headings: DIC is Debt Issuance Cost, OID is Original Issue Discount, Wts are warrants, CNC is Capitalized Note Cost and BCF is Beneficial Conversion Feature. Also included are repayments by conversion, exchange or otherwise during or prior to the three-month and nine-month periods ended September 30, 2023: The table below summarizes the convertible notes outstanding during the nine- months ended and as of September 30, 2023. There were several partial repayments made by conversion during the nine-months ended September 30, 2023: Schedule of Convertible Notes Outstanding Inception Date Maturity date Original Principal Amount Interest rate Original aggregate DIC, OID, Wts, CNC and BCF Cumulative amortization of DIC, OID, Wts, CNC and BCF Accrued coupon interest Repayment Consolidated balance sheet November 5, 2014 September 15, 2016 1 $ 25,000 10 % $ - $ - $ 34,066 $ - $ 59,066 November 5, 2014 September 15, 2016 1 25,000 10 % - - 34,066 - 59,066 November 5, 2014 September 15, 2016 1 25,000 12 % - - 44,806 - 69,806 Sub-total 75,000 - - 112,938 - 187,938 December 31, 2018 February 28, 2019 2 25,000 10 % - - 19,261 - 44,261 January 2, 2019 February 28, 2019 2 10,000 10 % - - 7,768 - 17,768 Sub-total 35,000 - - 27,029 - 62,029 May 17, 2019 May 17, 2020 3 50,000 10.00 % (50,000 ) 50,000 2,748 (50,000 ) 2,748 July 28, 2020 June 30, 2022 3 53,000 8.00 % (13,000 ) 13,000 11,937 (16,247 ) 48,690 February 17, 2021 June 17, 2022 3 112,000 10.00 % (112,000 ) 112,000 14,289 (98,000 ) 28,289 April 1, 2021 July 31, 2022 3 112,500 24.00 % (112,500 ) 112,500 39,775 (61,525 ) 90,750 May 3, 2021 July 31, 2022 3 150,000 10.00 % (150,000 ) 150,000 - (150,000 ) - May 10, 2021 August 10, 2022 3 150,000 10.00 % (150,000 ) 150,000 30,295 (28,213 ) 152,082 June 30, 2021 June 29, 2022 3 115,000 24.00 % (115,000 ) 115,000 42,030 - 157,030 August 31, 2021 August 31, 2022 3 115,000 10.00 % (109,675 ) 109,675 23,946 - 138,946 October 7, 2021 October 7, 2022 3 115,000 10.00 % (96,705 ) 96,705 22,779 - 137,779 December 23, 2021 June 21, 2022 3 87,000 24.00 % (36,301 ) 36,301 43,934 (54,060 ) 76,874 April 14, 2022 April 14, 2023 3 27,778 10.00 % (15,936 ) 15,936 4,064 - 31,842 August 22, 2022 May 31, 2023 3 66,667 10.00 % (6,667 ) 6,667 7,379 - 74,046 August 22, 2022 May 31, 2023 3 22,222 10.00 % (2,222 ) 2,222 2,460 - 24,682 August 22, 2022 May 31, 2023 3 16,667 10.00 % (1,667 ) 1,434 1,429 (16,500 ) 1,363 Sub-total 1,192,834 (971,673 ) 971,440 247,065 (474,545 ) 965,121 Total $ 1,302,834 $ (971,673 ) $ 971,440 $ 387,032 $ (474,545 ) $ 1,215,088 1 These convertible notes were sold to investors in 2014 and 2015 (“Original Convertible Notes) and have a fixed interest rate of 10 1,560 69,806 25,000 44,806 2 On December 31, 2018 and January 2, 2019, the Company issued convertible notes to a single investor totaling $ 35,000 27,029 3 These fourteen outstanding convertible notes were issued between May 17, 2019 and August 22, 2022. They all currently have similar terms including conversion prices that generally are or are likely to be $ 0.0015 Note Payable to SY Corporation Co., Ltd. On June 25, 2012, the Company borrowed 465,000,000 399,774 12 The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, dating back to January, August and September 2007, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds that the Company is no longer developing and where patent rights date back to January, August and September 2007. The security interest does not extend to the Company’s patents for its ampakine compounds CX1739 and CX1942 or certain related method of use patents. The note payable to SY Corporation consists of the following at September 30, 2023 and December 31, 2022: Schedule of Convertible Notes Payable September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 543,343 507,330 Foreign currency transaction adjustment (133,492 ) (73,641 ) Total note payable $ 809,625 $ 833,463 Interest expense with respect to this promissory note was $ 12,092 36,013 35,881 Notes Payable to Officers and Affiliates For the three-months ended September 30, 2023 and 2022, $ 3,753 3,412 11,136 10,124 225,000 446,305 In addition, Dr. Lippa periodically makes advances to the Company which are re-payable upon demand, do not accrue interest and are included in the total of notes payable to Officers. On May 22, 2023, RespireRx issued a demand promissory note in the principal amount of $ 225,000 10 75,000,000 0.0015 112,500 five years 5,671 8,075 On May 22, 2023, RespireRx issued a demand promissory note in the principal amount of $ 25,000 10 83,333,333 0.0015 12,500 one 630 897 Notes Payable to Former Officer For the three-months ended September 30, 2023 and 2022, $ 5,689 5,173 16,884 15,349 242,628 225,744 Other Short-Term Notes Payable Other short-term notes payable at September 30, 2023 and December 31, 2022 consisted primarily of premium financing agreements with respect to the Company’s directors and officers liability insurance policies. At September 30, 2023, a premium financing agreement was payable in the initial amount of $ 96,408 19,228 8.99 8,900 26,311 15,847

Settlement and Payment Agreemen

Settlement and Payment Agreements	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Settlement and Payment Agreements	5. Settlement and Payment Agreements On September 26, 2023, RespireRx entered into a Settlement and Exchange Agreement (“DNA Healthlink Agreement”) with DNA Healthlink, Inc. (“DNA Healthlink”), a vendor that provides the Company with the services of RespireRx’s Senior Vice President of Research and Development, Richard Purcell. Also on September 26, 2023, the Company and DNA Healthlink entered into the Second Amendment to Consulting Agreement (“Consulting Amendment”). Pursuant to the terms of the Settlement Agreement, the parties agreed that the Company owed DNA Healthlink $ 394,000 50,000 394,000 250 250 344,000 344,000 344,000 Pursuant to the terms of the Amendment, the RespireRx and DNA Healthlink agreed to amend the First Amendment to the Consulting Agreement dated October 15, 2014. The Consulting Amendment calls for RespireRx to prepay on a cash retainer basis, in installments of $ 5,000 250 5,000 5,000 The scope of the work is to be mutually agreed in advance in writing on a regular and as needed basis. In addition, the Consulting Amendment defined the term to be one-year and shall be automatically renewed for one-year renewal periods unless notice of cancellation is provided by either party within 30 days of September 26, 2024 or within 30 days of the end of any renewal period. Effective December 15, 2022, the Company and the Board of Trustees of the University of Illinois (“UIL”) entered into the Second Amendment to RespireRx -University of Illinois Exclusive License Agreement. The parties entered into the Second Amendment in order to eliminate accrued financial obligations to UIL and reduce future obligations. Annual $ 100,000 200,000 75,000 st 10,000 4 Effective August 1, 2022, the Company and the Company’s former legal counsel, entered into a payment settlement agreement and release pursuant to which the Company and its former legal counsel agreed that the Company owed $ 2,608,914 250,000 250,000 2,608,914 350,000 2,608,914 Effective January 31, 2022, the Company’s former President and Chief Executive Officer and Member of the Board of Directors, Timothy Jones, resigned his officer positions as well as from the Board of Directors pursuant to an Employment Agreement Termination and Separation Agreement (“SA”) dated February 8, 2022. Pursuant to the terms of the SA, the Company has agreed to pay Mr. Jones up to a maximum of $ 789,267 On April 29, 2021, RespireRx agreed to a payment and settlement agreement with the University of California Innovation and Entrepreneurship (“UIC”) with respect to accounts payable in an amount that was not in dispute and is reflected in accounts payable and accrued expenses in the Company’s condensed consolidated financial statements as of December 31, 2022 and June 30, 2023. The total amount due was $ 234,657 10,000 175,000 175,000 234,657 234,657 On February 21, 2020, Sharp Clinical Services, Inc. (“Sharp”), a vendor of the Company, filed a complaint against the Company in the Superior Court of New Jersey Law Division, Bergen County related to a December 16, 2019 demand for payment of past due invoices inclusive of late fees totaling $ 103,890 104,217 10,000 75,000 53,568 30,000 415 By letter dated February 5, 2016, the Company received a demand from a law firm representing Salamandra, LLC (“Salamandra”) alleging an amount due and owing for unpaid services rendered. On January 18, 2017, following an arbitration proceeding, an arbitrator awarded Salamandra the full amount sought in arbitration of $ 146,082 47,937 4.5 43,376 By email dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company in 2012 in conjunction with the Pier transaction alleging that $ 225,000 The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed consolidated financial statements (unaudited) as of September 30, 2023 and consolidated financial statements as of December 31, 2022 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously defend itself if any of the matters described above results in the filing of a lawsuit or formal claim.

Stockholders_ Deficiency

Stockholders’ Deficiency	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Deficiency	6. Stockholders’ Deficiency Preferred Stock RespireRx has authorized a total of 5,000,000 0.001 37,500 Series B Preferred Stock outstanding as of September 30, 2023 and December 31, 2022 consisted of 37,500 1 25,001 As of September 30, 2023, there were 1,376 On April 3, 2023, RespireRx authorized 3,500 8 0.001 100.00 8 0.02 0.0015 15,000,000 15,000,000 15,000,000 8 1,700 170,000 3,037 30 1,730 1,770 On April 12, 2023, RespireRx authorized 15,000 8 0.001 100.00 8 0.006 20,000,000 20,000,000 20,000,000 8 570,000 5,700 250 5,950 21,390 214 6,164 8,837 Although other series of preferred stock have been designated, no other shares of preferred stock are outstanding. As of September 30, 2023, 3,484,537 3,504,424 Common Stock RespireRx has authorized 2,000,000,000 0.001 298,328,647 133,639,999 39,144,372 630,558,175 31,039 0 74,100,000 0 39,144,372 33,401,107 96,712 2,923 1,000 100,635 67,090,000 0.0015 Common Stock Warrants A summary of warrant activity for the nine-months ended September 30, 2023 is presented below. Schedule of Warrant Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2022 419,683,183 $ 0.0074 3.38 Exercised (74,100,000 ) 0.0015 - Issued 83,333,333 - 4.65 Expired (33,401,307 ) - - Warrants outstanding and exercisable at September 30, 2023 395,515,209 $ 0.0023 3.26 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2023: Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable Exercise Warrants Expiration $ 0.0015 395,115,641 March 31, 2026 May 22, 2028 $ 0.03890 208,227 May 10, 2026 $ 0.0470 172,341 May 3, 2026 $ 15.0000 19,000 December 30, 2023 395,515,209 Based on a value of $ 0.0011 no A summary of warrant activity for the nine-months ended September 30, 2022 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2021 59,420,298 $ 0.0718 3.3300 Issued or repriced as a result of most favored nation provisions 187,927,001 0.0022 3.7392 Expired (2,317,150 ) (0.5121 ) - Warrants outstanding and exercisable at September 30, 2022 245,030,149 $ 0.0130 3.6753 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2022: Exercise Warrants Expiration $ 0.0015 171,852,001 August 31, 2026 April 14, 2027 $ 0.0100 46,450,000 September 30, 2023 April 14, 2027 $ 0.0200 927,273 September 30, 2023 $ 0.03890 208,227 May 10, 2026 $ 0.0470 172,341 May 3, 2026 $ 0.0700 25,377,426 September 30, 2023 $ 15.0000 15.7500 42,881 September 29, 2022 December 30, 2023 245,030,149 Based on a value of $ 0.0088 171,852,001 Stock Options On March 18, 2014, the stockholders of RespireRx holding a majority of the votes to be cast on the issue approved the adoption of RespireRx’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had been previously adopted by the Board of Directors, subject to stockholder approval. The Plan permits the grant of options and restricted stock in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company. As of September 30, 2023, there are 6,325 The 2014 Plan has provisions for the issuance of stock appreciation rights and phantom stock. On June 7, 2023, phantom stock awards (“Phantom Stock Awards”) totaling 306,000,000 Phantom Stock On June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (as amended, the “2015 Plan”). As of September 30, 2023, there are 13,701,149 Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock-based compensation costs and fees is provided at Note 3. A summary of stock option activity for the nine-months ended September 30, 2023 is presented below. Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2022 9,199,356 $ 0.592 3.74 Expired (31,039 ) 11.200 - Options outstanding and exercisable at September 30, 2023 9,168,317 $ 0.556 2.25 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2023: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Exercise Price Options Outstanding and Exercisable (Shares) Expiration Date $ 0.0190 2,194,444 December 31, 2026 $ 0.0540 1,700,000 September 30, 2025 $ 0.072 5,050,000 July 31, 2025 $ 7.00 159.25 223,873 November 21, 2023 December 9, 2027 9,168,317 There was no deferred compensation expense as there were no outstanding and unvested stock options at September 30, 2023. Based on a fair value of $ 0.0011 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2022: Exercise Price Options Outstanding and Exercisable (Shares) Expiration Date $ 0.0190 2,194,444 December 31, 2026 $ 0.0540 1,700,000 September 30, 2025 $ 0.072 5,050,000 July 31, 2025 $ 7.00 159.25 256,588 December 7, 2022 December 9, 2027 9,201,032 There was no deferred compensation expense for the outstanding and unvested stock options at September 30, 2022. Based on a fair value of $ 0.0088 Reserved and Unreserved Shares of Common Stock As of September 30, 2023, there are 2,000,000,000 0.001 298,328,647 9,168,317 6,325 13,701,149 652,721,529 395,515,209 1,071,113,178 Phantom Stock,

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Dr. Arnold S. Lippa and Jeff E. Margolis, officers and directors of RespireRx since March 22, 2013, have indirect ownership and managing membership interests in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis is also an officer of Aurora. Aurora, was a boutique investment banking firm specializing in the life sciences sector that ceased its securities related activities in April 2021 and withdrew its membership with FINRA and its registration with the SEC in July 2021. Although Aurora has not provided services to RespireRx during the nine-months ended September 30, 2023 or the fiscal year ended December 31, 2022, Aurora had previously provided services to RespireRx and there remains $ 96,000 A description of advances and notes payable to officers is provided at Note 4. Notes Payable.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Series I Preferred Stock See Note 6. Stockholders’ Deficiency – Preferred Stock Series J Preferred Stock See Note 6. Stockholders’ Deficiency – Preferred Stock Phantom Stock The features and terms of the Phantom Stock are delineated in Phantom Stock Award Agreements (“Phantom Stock Award Agreements”) which describe that the shares of Phantom Stock that were awarded are non-forfeitable but unvested on the award date which was June 7, 2023 and vest as to the economic value of 50% of the shares of Phantom Stock awarded on the first event payment date (“First Event Payment Date”) and as to the economic value of 50% of the shares of Phantom Stock awarded on the second event payment date (“Second Event Payment Date”) th Shares of Phantom Stock are not convertible, exercisable or exchangeable into RespireRx’s Common Stock. Upon the occurrence of a payment Event (“Payment Event”), RespireRx will incur a liability to each Participant that is to be remitted as a cash payment (“Payment”), subject to certain limitations as described below, equal to: (x) the number of vested shares of Phantom Stock held by such Participant, multiplied by (y) the fair market value which on any given day is the value of one share of Common Stock. The Payment, subject to any limitations, shall be made within thirty (30) days after receipt of funds by RespireRx as a result of the Payment Event, and all of such Participant’s shares of Phantom stock that vested as a result of the Payment Date Event shall terminate and be cancelled upon the payment, and the Participant shall have no further rights in respect of that portion of Participant’s shares of Phantom Stock other than rights to receive any unpaid portion of the Payment that was limited by any limitations described below. Any Payment due to a Participant is subject to the execution and non-revocation of general release of claims, in a form provided by RespireRx, and continuous compliance with any restrictive covenant agreement, confidentiality agreement or other agreement entered into between the Participant and RespireRx or its subsidiaries and affiliates. A Payment Event is a monetization event with an unrelated, unaffiliated third party, such as a sale of all or substantially all of an asset, the entering into a joint venture, license or sublicense or a similar transaction structure, that is not an equity or similar or debt investment in RespireRx or a subsidiary unless such equity or similar investment results in an unrelated, unaffiliated third party or group of parties acting together, resulting in such party or parties owning more than a 50 25,000,000 25,000,000 50,000,000 If the calculation of the payment based on the definition of Fair Market Value, exceeds 50% the amount of cash received by RespireRx with respect to a Payment Event, an initial payment shall be limited to 50% of the cash received by RespireRx with respect to the Payment Event and the unpaid balance shall be carried as a liability due to the Participant to be added to the payment amount of the Second Payment Event, subject to the same limitation Other than adjustments for stock splits, reverse stock splits, stock dividends and similar recapitalizations, the Phantom Stock Award Agreements do not provide for distributions or anti-dilution protections. Nothing contained in the Phantom Stock Award Agreements or RespireRx’s 2014 Equity Plan shall prevent RespireRx from adopting or continuing in effect other compensation arrangements. Jeff Margolis, and Arnold Lippa, each an officer and a director of RespireRx received awards of 120,000,000 70,000,000 20,000,000 96,000,000 306,000,000 The value of the Phantom Stock Awards cannot be determined at this time and can only be estimated or determined upon the occurrence of a Payment Event. Therefore, no amount has been recorded as a commitment or contingency. When or if a Payment Event occurs, an amount will be estimable or determinable and such amount will be recorded as a change in an estimate. Pending or Threatened Legal Action and Claims The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed consolidated financial statements (unaudited) as of September 30, 2023, consolidated financial statements as of December 31, 2022 and condensed consolidated financial statements (unaudited) as of September 30, 2022 with respect to such matters. See Note 5. Settlement and Payment Agreements for additional items and details. Significant Agreements and Contracts Consulting Agreements Richard Purcell, RespireRx’s Senior Vice President of Research and Development since October 15, 2014, has provided his services to RespireRx on an at will and month-to-month basis. On September 26, 2023 RespireRx and DNA Heathlink into the Second Amendment to Consulting Agreement (“Second Consulting Amendment”) and a Payment and Settlement Agreement (“DNA Healthlink Payment and Settlement Agreement”). Pursuant to the terms of the DNA Healthlink Payment and Settlement Agreement, the parties agreed that RespireRx owed DNA Healthlink $ 394,000 50,000 394,000 250 250 344,000 344,000 344,000 Pursuant to the terms of the Second Consulting Amendment, the Company and DNA Healthlink agreed to amend the First Amendment to the Consulting Agreement dated October 15, 2014 by calling for the Company to prepay on a cash retainer basis, in installments of $ 5,000 250 5,000 5,000 The scope of the work is to be mutually agreed in advance in writing on a regular and as needed basis. In addition, the Second Consulting Amendment established a term which was defined to be one-year and shall be automatically renewed for one-year renewal periods unless notice of cancellation is provided by either party within 30 days of September 26, 2024 or within 30 days of the end of any renewal period. During the nine-month period ended September 30, 2023 and the year ended December 31, 2022, Mr. Purcell did not provide any services to RespireRx. With the Second Consulting Amendment and the DNA Healthlink Payment and Settlement Agreement, the Company anticipates that Mr. Purcell will provide services to the Company during the fiscal year ending December 31, 2023. RespireRx entered into a consulting contract with David Dickason effective September 15, 2020 pursuant to which Mr. Dickason was appointed to and serves as RespireRx’s Senior Vice President of Pre-Clinical Product Development on an at-will basis at the rate of $ 250 Employment Agreements Effective on May 6, 2020, Timothy Jones was appointed as RespireRx’s President and Chief Executive Officer and entered into an employment agreement as of that date. Effective January 31 2022, Mr. Jones resigned as RespireRx’s President and Chief Executive Officer as well as a member of RespireRx’s Board of Directors pursuant to an Employment Agreement Termination and Separation Agreement dated February 8, 2022. See Note 5. Payment and Settlement Agreements. Effective January 31, 2022, Dr. Lippa was appointed as RespireRx’s Interim President and Interim Chief Executive Officer (“CEO”). Dr. Lippa continues to serve as RespireRx’s Executive Chairman and as a member of the Board of Directors as well as the Company’s Chief Scientific Officer (“CSO”). Effective January 11, 2023, Dr. Lippa was appointed as ResolutionRx’s Co-CEO and CSO and is a director of ResolutionRx. Jeff E. Margolis currently serves as RespireRx’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary. Mr. Margolis also serves on RespireRx’s Board of Directors. Effective January 11, 2023, Mr. Margolis was appointed as ResolutionRx’s Co-CEO and Senior Financial Officer and is a director of ResolutionRx. The table below summarized the current cash commitments to Dr. Lippa and Mr. Margolis through the next September 30 th Summary of Current Cash Commitments in Employee Agreements Contract year ending September 30, 2024 Twelve months Base Salary Benefits Total Arnold S. Lippa $ 300,000 $ 39,600 $ 339,600 Jeff E. Margolis 300,000 21,600 321,600 $ 600,000 $ 61,200 $ 661,200 Under certain circumstances base salaries may be contractually increased or the executives may become eligible for additional benefits and base salaries may be increased at the discretion of the Board of Directors. All executives are eligible for stock and stock option and similar grants at the discretion of the Board or Directors. The payment of certain amounts reflected in the table above have been voluntarily deferred indefinitely and payments against accrued compensation may be made based upon RespireRx’s ability to make such payments. ResolutionRx Services Agreement with iNGENu CRO Pty Ltd On February 27, 2023, ResolutionRx entered into a services agreement (“Australian CRO Agreement) with iNGENu CRO Pty Ltd (iNGENu), a contract research organization (“CRO”), pursuant to which iNGENu is to act as a full service CRO in support of ResolutionRx’s R&D program, including but not limited (a) preparing and (b) submitting regulatory documents and designing and conducting clinical trials. Under the Agreement, ResolutionRx was required to make a US$ 50,000 deposit which was paid. The deposit is to be applied to the final research and development budget which has been agreed by the parties. It also provides for mutual indemnifications, describes the relationship of the parties and that ResolutionRx retains ownership of all intellectual property and provides for confidentiality. ResolutionRx Master Services Agreement with Ab Initio On October 9, 2023, ResolutionRx Ltd (“ResolutionRx”) a wholly owned Australian, public, unlisted subsidiary of RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”) entered into a Master Services Agreement (“MSA”) with Ab Initio Pharma Pty Ltd, (“Ab Initio”) an Australian company for Ab Initio to manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx to ResolutionRx. The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test our new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials as well as ultimately for commercialization. The initial term of the MSA is two years and automatically renews for one-year periods unless ResolutionRx provides written notice to Ab Initio of its intent not to renew at least ninety days prior to the end of the initial term or any renewal term. The services to be provided are set forth in a work order attached as a schedule to the MSA. The MSA also provides for mutual indemnifications, describes the relationship of the parties and that ResolutionRx retains ownership of all intellectual property and provides for confidentiality. License Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx (“Licensor”) and ResolutionRx (“Licensee”), its wholly-owned, unlisted, public Australian subsidiary entered into a License Agreement (“License Agreement”) pursuant to which, RespireRx has licensed to ResolutionRx, the Intellectual Property (“Licensed IP” as defined in the License Agreement) which includes the Patent Rights (“Patent Rights” as defined in the License Agreement). The License (“License”) is an exclusive, worldwide and royalty-free license during the Term to use and exploit the Licensed IP in connection with ResolutionRx’s business and operations, including commercial and non-commercial purposes, with the exception that RespireRx shall have the exclusive right to use the technology described in the Licensed IP for non-cannabinoid products. ResolutionRx shall use its best efforts to commercialize the Licensed IP. The Licensed IP is basically, the intellectual property and patent rights, identified in Schedule A of the License Agreement and is associated with the new dronabinol formulation initially to be developed for the treatment of obstructive sleep apnea. The consideration for the License and the related Sublicense (see Sublicense Agreement between RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Share Transfer Agreement 25,000,000 1 Licensee shall not sublicense any of its rights and/or obligations under the License Agreement without the prior written consent of Licensor, except to contract manufacturers, distributors and other third parties engaged by Licensee pursuant to the normal course of Licensee’s business (the “ Sublicensees The Licensor shall be responsible for patent prosecution and maintenance and Licensee shall promptly either pay directly or reimburse Licensor’s costs in each jurisdiction. ResolutionRx as Licensee, at its option may control prosecution and maintenance of the Patent Rights. The License Agreement also addresses how the parties are to deal with interferences, if any. All unpublished information is to be treated confidentially. ResolutionRx acknowledges in the License Agreement, that RespireRx is the owner of all right, title and interest in and to the Licensed IP, including all modifications, enhancements, improvements and other derivative works (“Modifications”). All Modifications are Licensed IP immediately upon their creation. Licensee shall promptly notify Licensor of any actual or potential infringement, counterfeiting, or other unauthorized use of the Licensed IP by any other person or entity of which Licensee becomes aware. Licensor shall have the right, but not obligation, in its sole discretion, to enforce its rights in the Licensed IP, including to bring action with respect to any infringement of the Licensed IP. With respect to the Licensed Patents, the term of the License Agreement shall commence as of the Effective Date, as defined in the License Agreement, and shall be effective until the last of the Licensed Patents, as defined in the License Agreement, expires (the “ Patent Term Initial Term Renewal Term Licensee and Licensor have indemnified one another. The License Agreement is governed by and construed in accordance with Delaware Law, without regard to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction). Sublicense Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx as sublicensor (“Sublicensor”) and ResolutionRx as sublicensee (“Sublicensee”), entered into a Sublicense Agreement (“Sublicense Agreement”) whereby Sublicensor, sublicensed the rights to its Exclusive License Agreement with The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois (“ University Original License Letter Amendment Second Amendment Exclusive License The Exclusive License permits Sublicensor to grant written sublicenses of its rights under the Exclusive License. The consideration for the Sublicense and the related License (see License Agreement between RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Share Transfer Agreement 25,000,000 1 The Sublicense is essentially a direct pass-through of all of the rights and obligations associated with the Exclusive License from RespireRx as Sublicensor to ResolutionRx as Sublicensee. The Sublicense expires upon the termination of the Exclusive License. Stock Transfer Agreement with ResolutionRx Ltd On August 3, 2023, ResolutionRx as transferor (“Transferor”) and RespireRx as transferee (“Transferee”) entered into a Stock Transfer Agreement (“Stock Transfer Agreement”) whereby the Transferor and Transferee agreed that Transferor which has the authority under its Constitution to issue the 25,000,000 Master Intercompany Services Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx as the provider of services (“Provider”) and ResolutionRx as the recipient of services (“Recipient”) entered into a Master Intercompany Services Agreement (“MISA”). As of the date of the MISA, ResolutionRx was a wholly-owned Australian unlisted public subsidiary of RespireRx. Provider performs certain support activities in the form of both general and administrative and research and development support in the execution of the business operations of Recipient. The initial term of the MISA is from August 3, 2023 for two years. The MISA automatically renews for successive one-year periods unless Recipient gives written notice to Provider of its intent not to renew at least ninety days prior the end of the initial term or any renewal term. Provider will provide the services as set forth on Schedule A of the MISA on an ongoing basis as well as such further services as Recipient and Provider may specifically agree upon from time to time (the “Services”). As noted on Schedule A, and for clarity, Recipient specifically agrees to remit to Provider for the Services or components (“Components”) of the Services until such time as the Components are no longer required and when such Components are provided by a party in Australia other than Provider, or such Components are no longer subcontracted for by Provider and Provider agrees to no longer provide such Components or Services. The MISA also describes the selection of personnel and subcontracting. Provider will invoice Recipient for the Services to be performed on a quarterly basis (based on the fiscal year of Recipient) with such invoices to be issued, in advance, for Services to be rendered in the quarter following the date of each such invoice. Recipient will pay Provider a fee (“Fee”) as set forth on Schedule B of the MISA, which may be amended by the Parties from time to time. Only those costs and expenses wholly and exclusively or otherwise properly attributed to the provision and coordination of provision of the Services will be included in the calculation of the Fee. Fees are payable in US dollars unless otherwise agreed by the parties. Annually, based on the fiscal year of Recipient, Provider must deliver to Recipient its budget for the costs and expenses it reasonably believes will be incurred in the provision of the Services (“Budget”) which amounts may be increased by written agreement of Recipient and Provider. The Recipient and the Provider have each indemnified one another. The MISA also establishes confidentiality provisions. UWMRF Patent License Agreement On August 1, 2020, RespireRx exercised its option pursuant to its option agreement dated March 2, 2020, between RespireRx and UWM Research Foundation, an affiliate of the University of Wisconsin-Milwaukee (“UWMRF”). Upon exercise, RespireRx and UWMRF executed the UWMRF Patent License Agreement effective August 1, 2020 pursuant to which RespireRx licensed the identified intellectual property. Under the UWMRF Patent License Agreement, RespireRx has an exclusive license to commercialize GABAkine products based on UWMRF’s rights in certain patents and patent applications, and a non-exclusive license to commercialize products based on UWMRF’s rights in certain technology that is not the subject of the patents or patent applications. UWMRF maintains the right to use, and, upon the approval of RespireRx, to license, these patent and technology rights for any non-commercial purpose, including research and education. The UWMRF Patent License Agreement expires upon the later of the expiration of RespireRx’s payment obligations to UWMRF or the expiration of the last remaining licensed patent granted thereunder, subject to early termination upon the occurrence of certain events. The License Agreement also contains a standard indemnification provision in favor of UWMRF and confidentiality provisions obligating both parties. Under the UWMRF Patent License Agreement, in consideration for the licenses granted, RespireRx will pay to UWMRF the following: (i) patent filing and prosecution costs incurred by UWMRF prior to the effective date, paid in yearly installments over three years from the Effective Date; (ii) annual maintenance fees, beginning on the second anniversary of the Effective Date, which annual maintenance fees terminate upon RespireRx’s payment of royalties pursuant to clause (iv) below; (iii) milestone payments, paid upon the occurrence of certain dosing events of patients during clinical trials and certain approvals by the FDA; and (iv) royalties on net sales of products developed with the licenses, subject to minimum annual payments and to royalty rate adjustments based on whether separate royalty payments by RespireRx yield an aggregate rate beyond a stated threshold. RespireRx will pay to UWMRF certain percentages of revenues generated from sublicenses of the licenses provided under the UWMRF Patent License Agreement by RespireRx to third parties. Certain payments under the UWMRF Patent License Agreement have not been paid by RespireRx. RespireRx is in regular discussions with UWMRF regarding when RespireRx may be able to commence making payments. RespireRx has not received a notification of default either during or before the nine-month period ended September 30, 2023 or in any subsequent periods. All amounts due under the UWMRF Patent License Agreement are reflected in the Company’s condensed consolidated financial statements as of September 30, 2023 and December 31, 2022 in accounts payable and accrued expenses. University of Wisconsin-Milwaukee Outreach Services Agreement On July 12, 2021, RespireRx and the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Milwaukee (“UWM”) entered into an Outreach Services Agreement pursuant to which UWM agreed to provide, among other molecules, multiple milligram to gram quantities of KRM-II-81 (GABAkine) and RespireRx agreed to pay UWM an annual sum of $ 75,000 25,000 50,000 35,185 30,185 50 5,000 University of Illinois 2014 Exclusive License Agreement On June 27, 2014, RespireRx entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including: (i) the payment by RespireRx of a $ 25,000 15,840 nd The 2014 License Agreement granted RespireRx (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea. Among other things, the 2 nd nd nd 4 The 2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015. In addition, the 2014 License Agreement provides for various royalty payments, including a royalty on net sales of 4 12.5 100,000 100,000 100,000 0 350,000 150,000 200,000 250,000 (i) $ 10,000 (ii) $ 150,000 (iii) $ 350,000 (iv) $ 500,000 (v) $ 1,000,000 There are reporting requirements by the Licensee to the University. Royalty stacking provisions remained unchanged in the 2 nd The concept of reduced royalties upon expiration of the patent rights, but while technical information was being used, was eliminated with the 2 nd During the nine-months ended September, 2023 and 2022, the Company recorded charges to operations of $ 0 50,000 100,000 nd 0 Noramco Inc. - Dronabinol Development and Supply Agreement On September 4, 2018, RespireRx entered into a dronabinol Development and Supply Agreement with Noramco Inc., one of the world’s major dronabinol manufacturers, which Noramco subsequently assigned to its subsidiary, Purisys LLC (the “Purisys Agreement”). Under the terms of the Purisys Agreement, Purisys agreed to (i) provide all of the active pharmaceutical ingredient (“API”) estimated to be needed for the clinical development process for both the first- and second-generation products (each a “Product” and collectively, the “Products”), three validation batches for New Drug Application (“NDA”) filing(s) and adequate supply for the initial inventory stocking for the wholesale and retail channels, subject to certain limitations, (ii) maintain or file valid drug master files (“DMFs”) with the FDA or any other regulatory authority and provide RespireRx with access or a right of reference letter entitling RespireRx to make continuing reference to the DMFs during the term of the agreement in connection with any regulatory filings made with the FDA by RespireRx, (iii) participate on a development committee, and (iv) make available its regulatory consultants, collaborate with any regulatory consulting firms engaged by RespireRx and participate in all FDA or Drug Enforcement Agency (“DEA”) meetings as appropriate and as related to the API. We now refer to the second-generation product as our proprietary formulation or proprietary product and have de-emphasized the first-generation product. In consideration for these supplies and services, RespireRx has agreed to purchase exclusively from Noramco during the commercialization phase all API for its Products as defined in the Development and Supply Agreement at a pre-determined price subject to certain producer price adjustments and agreed to Noramco’s participation in the economic success of the commercialized Product or Products up to the earlier of the achievement of a maximum dollar amount or the expiration of a period of time. There was no activity during the nine-month periods ended September 30, 2023 or 2022 with respect to the Purisys Agreement. The Company is engaging in discussions with Purisys with the intent of amending the Purisys Agreement or cancelling the Purisys Agreement and establishing a new agreement. The anticipated new formulations and the formation of ResolutionRx in Australia are the primary reasons for participating in such discussions. Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of September 30, 2023, aggregating $ 751,385 Summary of Principal Cash Obligations and Commitments Payments Due By Year Total 2023 2024 2025 2026 2027 License agreements $ 90,185 $ 35,185 $ 10,000 $ 15,000 $ 15,000 $ 15,000 Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 751,385 $ 200,485 $ 505,900 $ 15,000 $ 15,000 $ 15,000 (1) The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements.”

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events Post September 30, 2023 Convertible Note Conversions During the period from October 1, 2023 through November 9, 2023, three convertible note holders of notes with substantially similar attributes converted $ 96,712 2,923 1,000 100,635 67,090,000 0.0015 On November 7, 2023, RespireRx received a $ 25,000 250 Patent fees and maintenance fees of $35,185 due to UWMRF at August 1, 2023 were unpaid Payment due of $ 35,185 30,185 50 5,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements (unaudited) are prepared in accordance with GAAP and include the financial statements of RespireRx and its wholly-owned subsidiaries, Pier and ResolutionRx. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.
Value of Financial Instruments	Value of Financial Instruments The authoritative guidance with respect to value of financial instruments established a value hierarchy that prioritizes the inputs to valuation techniques used to measure value into three levels and requires that assets and liabilities carried at value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the value hierarchy within which each value measurement falls in its entirety, based on the lowest level input that is significant to the value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, and accounts payable and accrued expenses) are considered by the Company to be representative of the respective values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date for companies like the Company. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective values of such instruments due to the short-term nature of those instruments and their terms.
Capitalized Financing Costs	Capitalized Financing Costs The Company presents debt issuance costs related to debt obligations in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt obligation, consistent with the presentation for debt discounts.
Convertible Notes Payable	Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants, commitment shares of Common Stock, the convertible notes and equity or equity-linked securities are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued in connection with and at the time of such financing.
Debt and Other Liability Exchanges	Debt and Other Liability Exchanges In cases where debt or other liabilities are exchanged for equity, the Company compares the carrying value of debt, inclusive of accrued interest, if applicable, being exchanged, to the fair value of the equity issued and records any loss or gain as a result of such exchange. See Note 4. Notes Payable.
Extinguishment of Debt and Settlement of Liabilities	Extinguishment of Debt and Settlement of Liabilities The Company accounts for the extinguishment of debt and settlement of liabilities by comparing the carrying value of the debt or liability to the value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs.
Prepaid Insurance	Prepaid Insurance Prepaid insurance represents the premium that was due in March 2023 for directors and officers insurance. The amounts of prepaid insurance amortizable in the ensuing twelve-month period are recorded as prepaid insurance in the Company’s consolidated balance sheet at each reporting date and amortized to the Company’s consolidated statement of operations for each reporting period.
Stock-Based Awards	Stock-Based Awards The Company periodically issues common stock, stock options and phantom stock (collectively, “Stock-Based Awards”) to officers, directors, Scientific Advisory Board members, consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated or condensed consolidated financial statements over the vesting period of the awards. Stock grants, which are sometimes subject to time-based vesting, are measured at the grant date fair value of the common stock and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s outside consultants and other vendors are valued on the grant date. As the stock options vest, the Company recognizes this expense over the period in which the services are provided. The value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock and stock option grants and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. Phantom stock awards, which are sometimes subject to time-based vesting, are measured at the award date fair value, if measurable. As the phantom stock awards vest, the Company recognizes the expense, if measurable, upon vesting. To the extent that the value of phantom stock awards is not measurable on the award date, measurement only being possible on the satisfaction of certain contingent events that may not be predictable and measurable at the time of the award, the Company recognizes the expense as a change in an estimate as of the date on which the contingent event becomes predictable and measurable. The Company recognizes the value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated or condensed consolidated statements of operations, as appropriate. The Company issues new shares of Common Stock to satisfy stock option and warrant exercises. There were no There were no There were no 83,333,333 250,000
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, management does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2023, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2023 and December 31, 2022, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Foreign Currency Transactions	Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The accounts for ResolutionRx are maintained in Australian dollars and are converted to U.S. dollars at the exchange rate on the balance sheet. In both cases, the foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations.
Research and Development	Research and Development Research and development costs include compensation paid to management directing the Company’s R&D activities, including but not limited to compensation paid to our Chief Scientific Officer who is also our Executive Chairman, Interim President and Interim Chief Executive Officer, and who has similar roles at ResolutionRx, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, research, development and clinical testing of the Company’s treatments and product candidates.
License Agreements	License Agreements Obligations incurred with respect to mandatory payments provided for in-license agreements are recognized ratably over the appropriate term, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in-license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development expenses in the Company’s condensed consolidated statement of operations.
Patent Costs	Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses.
Earnings (Loss) per Share	Earnings (Loss) per Share The Company’s computation of earnings (loss) per common share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net loss attributable to common stockholders consists of net loss, as adjusted for actual and deemed stock dividends declared, accrued, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2023 and 2022 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 September 30, 2023 2022 Series B convertible preferred stock 1 1 Convertible notes payable 652,721,528 348,938,988 Common stock warrants 395,515,209 245,030,149 Common stock options 9,168,317 9,201,032 Total 1,057,405,055 603,170,170
Reclassifications	Reclassifications Certain comparative figures in 2022 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	At September 30, 2023 and 2022 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 September 30, 2023 2022 Series B convertible preferred stock 1 1 Convertible notes payable 652,721,528 348,938,988 Common stock warrants 395,515,209 245,030,149 Common stock options 9,168,317 9,201,032 Total 1,057,405,055 603,170,170

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2023
Schedule of Convertible Notes Outstanding	The table below summarizes the convertible notes outstanding during the nine- months ended and as of September 30, 2023. There were several partial repayments made by conversion during the nine-months ended September 30, 2023: Schedule of Convertible Notes Outstanding Inception Date Maturity date Original Principal Amount Interest rate Original aggregate DIC, OID, Wts, CNC and BCF Cumulative amortization of DIC, OID, Wts, CNC and BCF Accrued coupon interest Repayment Consolidated balance sheet November 5, 2014 September 15, 2016 1 $ 25,000 10 % $ - $ - $ 34,066 $ - $ 59,066 November 5, 2014 September 15, 2016 1 25,000 10 % - - 34,066 - 59,066 November 5, 2014 September 15, 2016 1 25,000 12 % - - 44,806 - 69,806 Sub-total 75,000 - - 112,938 - 187,938 December 31, 2018 February 28, 2019 2 25,000 10 % - - 19,261 - 44,261 January 2, 2019 February 28, 2019 2 10,000 10 % - - 7,768 - 17,768 Sub-total 35,000 - - 27,029 - 62,029 May 17, 2019 May 17, 2020 3 50,000 10.00 % (50,000 ) 50,000 2,748 (50,000 ) 2,748 July 28, 2020 June 30, 2022 3 53,000 8.00 % (13,000 ) 13,000 11,937 (16,247 ) 48,690 February 17, 2021 June 17, 2022 3 112,000 10.00 % (112,000 ) 112,000 14,289 (98,000 ) 28,289 April 1, 2021 July 31, 2022 3 112,500 24.00 % (112,500 ) 112,500 39,775 (61,525 ) 90,750 May 3, 2021 July 31, 2022 3 150,000 10.00 % (150,000 ) 150,000 - (150,000 ) - May 10, 2021 August 10, 2022 3 150,000 10.00 % (150,000 ) 150,000 30,295 (28,213 ) 152,082 June 30, 2021 June 29, 2022 3 115,000 24.00 % (115,000 ) 115,000 42,030 - 157,030 August 31, 2021 August 31, 2022 3 115,000 10.00 % (109,675 ) 109,675 23,946 - 138,946 October 7, 2021 October 7, 2022 3 115,000 10.00 % (96,705 ) 96,705 22,779 - 137,779 December 23, 2021 June 21, 2022 3 87,000 24.00 % (36,301 ) 36,301 43,934 (54,060 ) 76,874 April 14, 2022 April 14, 2023 3 27,778 10.00 % (15,936 ) 15,936 4,064 - 31,842 August 22, 2022 May 31, 2023 3 66,667 10.00 % (6,667 ) 6,667 7,379 - 74,046 August 22, 2022 May 31, 2023 3 22,222 10.00 % (2,222 ) 2,222 2,460 - 24,682 August 22, 2022 May 31, 2023 3 16,667 10.00 % (1,667 ) 1,434 1,429 (16,500 ) 1,363 Sub-total 1,192,834 (971,673 ) 971,440 247,065 (474,545 ) 965,121 Total $ 1,302,834 $ (971,673 ) $ 971,440 $ 387,032 $ (474,545 ) $ 1,215,088 1 These convertible notes were sold to investors in 2014 and 2015 (“Original Convertible Notes) and have a fixed interest rate of 10 1,560 69,806 25,000 44,806 2 On December 31, 2018 and January 2, 2019, the Company issued convertible notes to a single investor totaling $ 35,000 27,029 3 These fourteen outstanding convertible notes were issued between May 17, 2019 and August 22, 2022. They all currently have similar terms including conversion prices that generally are or are likely to be $ 0.0015
SY Corporation [Member]
Schedule of Convertible Notes Payable	The note payable to SY Corporation consists of the following at September 30, 2023 and December 31, 2022: Schedule of Convertible Notes Payable September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 543,343 507,330 Foreign currency transaction adjustment (133,492 ) (73,641 ) Total note payable $ 809,625 $ 833,463

Stockholders_ Deficiency (Table

Stockholders’ Deficiency (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the nine-months ended September 30, 2023 is presented below. Schedule of Warrant Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2022 419,683,183 $ 0.0074 3.38 Exercised (74,100,000 ) 0.0015 - Issued 83,333,333 - 4.65 Expired (33,401,307 ) - - Warrants outstanding and exercisable at September 30, 2023 395,515,209 $ 0.0023 3.26 A summary of warrant activity for the nine-months ended September 30, 2022 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2021 59,420,298 $ 0.0718 3.3300 Issued or repriced as a result of most favored nation provisions 187,927,001 0.0022 3.7392 Expired (2,317,150 ) (0.5121 ) - Warrants outstanding and exercisable at September 30, 2022 245,030,149 $ 0.0130 3.6753
Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable	The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2023: Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable Exercise Warrants Expiration $ 0.0015 395,115,641 March 31, 2026 May 22, 2028 $ 0.03890 208,227 May 10, 2026 $ 0.0470 172,341 May 3, 2026 $ 15.0000 19,000 December 30, 2023 395,515,209 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2022: Exercise Warrants Expiration $ 0.0015 171,852,001 August 31, 2026 April 14, 2027 $ 0.0100 46,450,000 September 30, 2023 April 14, 2027 $ 0.0200 927,273 September 30, 2023 $ 0.03890 208,227 May 10, 2026 $ 0.0470 172,341 May 3, 2026 $ 0.0700 25,377,426 September 30, 2023 $ 15.0000 15.7500 42,881 September 29, 2022 December 30, 2023 245,030,149
Summary of Stock Option Activity	A summary of stock option activity for the nine-months ended September 30, 2023 is presented below. Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2022 9,199,356 $ 0.592 3.74 Expired (31,039 ) 11.200 - Options outstanding and exercisable at September 30, 2023 9,168,317 $ 0.556 2.25
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2023: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Exercise Price Options Outstanding and Exercisable (Shares) Expiration Date $ 0.0190 2,194,444 December 31, 2026 $ 0.0540 1,700,000 September 30, 2025 $ 0.072 5,050,000 July 31, 2025 $ 7.00 159.25 223,873 November 21, 2023 December 9, 2027 9,168,317 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2022: Exercise Price Options Outstanding and Exercisable (Shares) Expiration Date $ 0.0190 2,194,444 December 31, 2026 $ 0.0540 1,700,000 September 30, 2025 $ 0.072 5,050,000 July 31, 2025 $ 7.00 159.25 256,588 December 7, 2022 December 9, 2027 9,201,032

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of Current Cash Commitments in Employee Agreements	The table below summarized the current cash commitments to Dr. Lippa and Mr. Margolis through the next September 30 th Summary of Current Cash Commitments in Employee Agreements Contract year ending September 30, 2024 Twelve months Base Salary Benefits Total Arnold S. Lippa $ 300,000 $ 39,600 $ 339,600 Jeff E. Margolis 300,000 21,600 321,600 $ 600,000 $ 61,200 $ 661,200
Summary of Principal Cash Obligations and Commitments	Summary of Principal Cash Obligations and Commitments Payments Due By Year Total 2023 2024 2025 2026 2027 License agreements $ 90,185 $ 35,185 $ 10,000 $ 15,000 $ 15,000 $ 15,000 Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 751,385 $ 200,485 $ 505,900 $ 15,000 $ 15,000 $ 15,000 (1) The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements.”

Business (Details Narrative)

Business (Details Narrative) - USD ($)			3 Months Ended						9 Months Ended		12 Months Ended
	May 18, 2023	Jan. 27, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Sep. 26, 2023	May 11, 2023	Dec. 31, 2021
Ordinary shares													25,000,000
Net losses			$ 395,502	$ 681,030	$ 430,063	$ 472,578	$ 480,288	$ 860,163	$ 1,506,595	$ 1,813,029
Net loss attributable to common stockholders			409,169			1,641,172			1,531,022	3,333,361	$ 3,972,993
Negative operating cash flows									258,726	155,061	143,905
Equity, Attributable to Parent			12,296,454	$ 12,142,352	$ 12,310,383	$ 11,590,629	$ 11,131,459	$ 10,867,921	12,296,454	$ 11,590,629	$ 11,880,320			$ 10,007,758
Maturity amount			$ 1,215,088						$ 1,215,088
Amounts owed												$ 50,000
Series I 8% Redeemable Preferred Stock [Member]
Amounts owed												25,000
Series J 8% Redeemable Preferred Stock [Member]
Amounts owed												$ 25,000
Cantheon Capital [Member]
Intended investment	$ 125,000
Clinical trail costs percentage	25%
Letter Of Intent [Member]
Debt instrument description		ResolutionRx is eligible to participate in the Australian R&D Tax Incentive (“R&DTI”), which is a tax rebate by the Australian government for qualified R&D expenditures. In the case of ResolutionRx, the R&DTI is expected to be 43.5% of qualified R&D. On January 27, 2023, ResolutionRx entered into a Letter of Intent and a term sheet with Radium Capital pursuant to which Radium Capital will finance in accordance with a debt facility, 80% or ResolutionRx’s of 43.5% tax rebate on an ongoing application basis similar to a line of credit.

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,057,405,055	603,170,170
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1	1
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	652,721,528	348,938,988
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	395,515,209	245,030,149
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,168,317	9,201,032

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	May 22, 2023
Number of stock grants	0	0	0	0
Stock options exercised	0	0	0	0
Warrants issued as compensation or service	$ 0	$ 0	$ 0	$ 0
Warrants exercisable shares					83,333,333
Officer and Affiliate [Member]
Warrants issued					$ 250,000

Schedule of Convertible Notes O

Schedule of Convertible Notes Outstanding (Details)	9 Months Ended
	Sep. 30, 2023 USD ($)
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Original Principal Amount	$ 1,302,834
Original aggregate DIC, OID, Wts, CNC and BCF	(971,673)
Cumulative amortization of DIC, OID, Wts, CS and BCF	971,440
Accrued coupon interest	387,032
Repayment by conversion	(474,545)
Consolidated balance sheet carrying amount inclusive of accrued interest	1,215,088
Debt Conversion, Original Debt, Amount	$ 971,673
November 5, 2014 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Sep. 15, 2016	[1]
Original Principal Amount	$ 25,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF
Cumulative amortization of DIC, OID, Wts, CS and BCF
Accrued coupon interest	34,066
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	59,066
Debt Conversion, Original Debt, Amount
November 5, 2014 One [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Sep. 15, 2016	[1]
Original Principal Amount	$ 25,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF
Cumulative amortization of DIC, OID, Wts, CS and BCF
Accrued coupon interest	34,066
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	59,066
Debt Conversion, Original Debt, Amount
November 5, 2014 Two [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Sep. 15, 2016	[1]
Original Principal Amount	$ 25,000
Interest rate	12%
Original aggregate DIC, OID, Wts, CNC and BCF
Cumulative amortization of DIC, OID, Wts, CS and BCF
Accrued coupon interest	44,806
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	69,806
Debt Conversion, Original Debt, Amount
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Original Principal Amount	75,000
Original aggregate DIC, OID, Wts, CNC and BCF
Cumulative amortization of DIC, OID, Wts, CS and BCF
Accrued coupon interest	112,938
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	187,938
Debt Conversion, Original Debt, Amount
December 31, 2018 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Feb. 28, 2019	[2]
Original Principal Amount	$ 25,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF
Cumulative amortization of DIC, OID, Wts, CS and BCF
Accrued coupon interest	19,261
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	44,261
Debt Conversion, Original Debt, Amount
January 2, 2019 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Feb. 28, 2019	[2]
Original Principal Amount	$ 10,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF
Cumulative amortization of DIC, OID, Wts, CS and BCF
Accrued coupon interest	7,768
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	17,768
Debt Conversion, Original Debt, Amount
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Original Principal Amount	35,000
Original aggregate DIC, OID, Wts, CNC and BCF
Cumulative amortization of DIC, OID, Wts, CS and BCF
Accrued coupon interest	27,029
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	62,029
Debt Conversion, Original Debt, Amount
May 17, 2019 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	May 17, 2020	[3]
Original Principal Amount	$ 50,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (50,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF	50,000
Accrued coupon interest	2,748
Repayment by conversion	(50,000)
Consolidated balance sheet carrying amount inclusive of accrued interest	2,748
Debt Conversion, Original Debt, Amount	$ 50,000
July 28, 2020 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jun. 30, 2022	[3]
Original Principal Amount	$ 53,000
Interest rate	8%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (13,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF	13,000
Accrued coupon interest	11,937
Repayment by conversion	(16,247)
Consolidated balance sheet carrying amount inclusive of accrued interest	48,690
Debt Conversion, Original Debt, Amount	$ 13,000
February 17, 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jun. 17, 2022	[3]
Original Principal Amount	$ 112,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (112,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF	112,000
Accrued coupon interest	14,289
Repayment by conversion	(98,000)
Consolidated balance sheet carrying amount inclusive of accrued interest	28,289
Debt Conversion, Original Debt, Amount	$ 112,000
April 1, 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jul. 31, 2022	[3]
Original Principal Amount	$ 112,500
Interest rate	24%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (112,500)
Cumulative amortization of DIC, OID, Wts, CS and BCF	112,500
Accrued coupon interest	39,775
Repayment by conversion	(61,525)
Consolidated balance sheet carrying amount inclusive of accrued interest	90,750
Debt Conversion, Original Debt, Amount	$ 112,500
May 3, 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jul. 31, 2022	[3]
Original Principal Amount	$ 150,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (150,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF	150,000
Accrued coupon interest
Repayment by conversion	(150,000)
Consolidated balance sheet carrying amount inclusive of accrued interest
Debt Conversion, Original Debt, Amount	$ 150,000
May 10, 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Aug. 10, 2022	[3]
Original Principal Amount	$ 150,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (150,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF	150,000
Accrued coupon interest	30,295
Repayment by conversion	(28,213)
Consolidated balance sheet carrying amount inclusive of accrued interest	152,082
Debt Conversion, Original Debt, Amount	$ 150,000
June 30, 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jun. 29, 2022	[3]
Original Principal Amount	$ 115,000
Interest rate	24%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (115,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF	115,000
Accrued coupon interest	42,030
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	157,030
Debt Conversion, Original Debt, Amount	$ 115,000
August 31, 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Aug. 31, 2022	[3]
Original Principal Amount	$ 115,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (109,675)
Cumulative amortization of DIC, OID, Wts, CS and BCF	109,675
Accrued coupon interest	23,946
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	138,946
Debt Conversion, Original Debt, Amount	$ 109,675
October 7, 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Oct. 07, 2022	[3]
Original Principal Amount	$ 115,000
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (96,705)
Cumulative amortization of DIC, OID, Wts, CS and BCF	96,705
Accrued coupon interest	22,779
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	137,779
Debt Conversion, Original Debt, Amount	$ 96,705
December 23, 2021 Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jun. 21, 2022	[3]
Original Principal Amount	$ 87,000
Interest rate	24%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (36,301)
Cumulative amortization of DIC, OID, Wts, CS and BCF	36,301
Accrued coupon interest	43,934
Repayment by conversion	(54,060)
Consolidated balance sheet carrying amount inclusive of accrued interest	76,874
Debt Conversion, Original Debt, Amount	$ 36,301
April 14, 2022 [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Apr. 14, 2023	[3]
Original Principal Amount	$ 27,778
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (15,936)
Cumulative amortization of DIC, OID, Wts, CS and BCF	15,936
Accrued coupon interest	4,064
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	31,842
Debt Conversion, Original Debt, Amount	$ 15,936
August 22, 2022 One [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	May 31, 2023	[3]
Original Principal Amount	$ 66,667
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (6,667)
Cumulative amortization of DIC, OID, Wts, CS and BCF	6,667
Accrued coupon interest	7,379
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	74,046
Debt Conversion, Original Debt, Amount	$ 6,667
August 22, 2022 Two [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	May 31, 2023	[3]
Original Principal Amount	$ 22,222
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (2,222)
Cumulative amortization of DIC, OID, Wts, CS and BCF	2,222
Accrued coupon interest	2,460
Repayment by conversion
Consolidated balance sheet carrying amount inclusive of accrued interest	24,682
Debt Conversion, Original Debt, Amount	$ 2,222
August 22, 2022 Three [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	May 31, 2023	[3]
Original Principal Amount	$ 16,667
Interest rate	10%
Original aggregate DIC, OID, Wts, CNC and BCF	$ (1,667)
Cumulative amortization of DIC, OID, Wts, CS and BCF	1,434
Accrued coupon interest	1,429
Repayment by conversion	(16,500)
Consolidated balance sheet carrying amount inclusive of accrued interest	1,363
Debt Conversion, Original Debt, Amount	1,667
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Original Principal Amount	1,192,834
Original aggregate DIC, OID, Wts, CNC and BCF	(971,673)
Cumulative amortization of DIC, OID, Wts, CS and BCF	971,440
Accrued coupon interest	247,065
Repayment by conversion	(474,545)
Consolidated balance sheet carrying amount inclusive of accrued interest	965,121
Debt Conversion, Original Debt, Amount	$ 971,673
[1]These convertible notes were sold to investors in 2014 and 2015 (“Original Convertible Notes) and have a fixed interest rate of 10 1,560 69,806 25,000 44,806 35,000 27,029 0.0015

Schedule of Convertible Notes_2

Schedule of Convertible Notes Outstanding (Details) (Parenthetical) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Conversion of common stock	133,639,999
Original Convertible Notes [Member]
Short-Term Debt [Line Items]
Fixed interest rate	10%
Conversion of common stock	1,560
Convertible notes	$ 69,806
Principal amount	25,000
Accrued interest	44,806
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Accrued interest	387,032	$ 327,881
Convertible Notes Payable [Member] | Single Investor [Member]
Short-Term Debt [Line Items]
Convertible notes	35,000
Accrued interest	$ 27,029
Fourteen Outstanding Convertible Notes [Member]
Short-Term Debt [Line Items]
Common stock, per share	$ 0.0015

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - SY Corporation [Member]	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jun. 25, 2012 USD ($)	Jun. 25, 2012 KRW (₩)
Principal amount of note payable	$ 399,774	$ 399,774	$ 399,774	₩ 465,000,000
Accrued interest payable	543,343	507,330
Foreign currency transaction adjustment	(133,492)	(73,641)
Total note payable	$ 809,625	$ 833,463

Notes Payable (Details Narrativ

Notes Payable (Details Narrative)		1 Months Ended	3 Months Ended		9 Months Ended
	May 22, 2023 USD ($) $ / shares shares	May 31, 2023 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Jun. 25, 2012 USD ($)	Jun. 25, 2012 KRW (₩)
Short-Term Debt [Line Items]
Interest expense			$ 73,408	$ 94,643	$ 365,729	$ 533,812
Notes payable, advances and accrued interest			$ 35,185		$ 35,185
Warrant purchase | shares			395,515,209		395,515,209
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.0011	$ 0.0088	$ 0.0011	$ 0.0088
Nine Monthly Installments [Member]
Short-Term Debt [Line Items]
Debt periodic payments					$ 8,900
Other Short-Term Notes Payable [Member]
Short-Term Debt [Line Items]
Interest rate percentage			8.99%		8.99%
Insurance premium			$ 96,408		$ 96,408
Insurance deposits paid		$ 19,228
Short-term notes payable			26,311		26,311		$ 15,847
Measurement Input, Option Volatility [Member]
Short-Term Debt [Line Items]
Exercise period in years	1 year
Related Party [Member]
Short-Term Debt [Line Items]
Notes payable, advances and accrued interest			446,305		446,305
Dr Manuso [Member]
Short-Term Debt [Line Items]
Notes payable, advances and accrued interest			242,628		242,628		225,744
Dr Arnold S Lippa [Member]
Short-Term Debt [Line Items]
Interest expense			3,753	$ 3,412	11,136	$ 10,124
Convertible Debt			225,000		225,000
Arnold Lippa [Member]
Short-Term Debt [Line Items]
Interest rate percentage	10%
Accrued Liabilities, Current	$ 225,000
Warrant purchase | shares	75,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.0015
Warrants and Rights Outstanding	$ 112,500
Interest expense			5,671		8,075
Arnold Lippa [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Exercise period in years	5 years
Director [Member]
Short-Term Debt [Line Items]
Interest rate percentage	10%
Accrued Liabilities, Current	$ 25,000
Warrant purchase | shares	83,333,333
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.0015
Warrants and Rights Outstanding	$ 12,500
Interest expense			630		897
Dr.James S Manusos [Member]
Short-Term Debt [Line Items]
Interest expense			5,689	5,173	16,884	15,349
SY Corporation [Member]
Short-Term Debt [Line Items]
Original Principal Amount			399,774		399,774		$ 399,774	$ 399,774	₩ 465,000,000
Interest rate percentage								12%	12%
Interest expense			$ 12,092	$ 12,092	$ 36,013	$ 35,881

Settlement and Payment Agreem_2

Settlement and Payment Agreements (Details Narrative) - USD ($)

6 Months Ended

9 Months Ended

Sep. 26, 2023

Mar. 28, 2022

Aug. 01, 2021

May 29, 2020

Feb. 21, 2020

Jan. 18, 2017

Jun. 30, 2023

Sep. 30, 2023

Feb. 15, 2023

Dec. 31, 2022

Dec. 30, 2022

Dec. 15, 2022

Aug. 01, 2022

Mar. 31, 2022

Jan. 31, 2022

Dec. 31, 2021

Apr. 29, 2021

Feb. 26, 2018

Jul. 21, 2016

Debt Instrument [Line Items]

Accounts payable

$ 6,627,788

$ 5,724,390

Accounts payable

$ 50,000

Due to related parties, current

35,185

Related Party [Member]

Debt Instrument [Line Items]

Due to related parties, current

446,305

Sharp Clinical Services Inc [Member]

Debt Instrument [Line Items]

Late payment fees

$ 103,890

Loss contingency, value

$ 104,217

Payments for legal settlements

$ 75,000

$ 10,000

Payments for fees

$ 415

Sharp Clinical Services Inc [Member] | Related Party [Member]

Debt Instrument [Line Items]

Due to related parties, current

53,568

Salamandra LLC [Member]

Debt Instrument [Line Items]

Attorneys fees and cost

$ 47,937

Percentage of accrued interest

4.50%

Accrued interest

43,376

Salamandra LLC [Member] | Related Party [Member]

Debt Instrument [Line Items]

Due to related parties, current

$ 146,082

Investment Banking Services [Member]

Debt Instrument [Line Items]

Accrued expenses

$ 225,000

Series I 8% Redeemable Preferred Stock [Member]

Debt Instrument [Line Items]

Share issued

250

Accounts payable

$ 25,000

Series J 8% Redeemable Preferred Stock [Member]

Debt Instrument [Line Items]

Share issued

250

Accounts payable

$ 25,000

Settlement Agreement [Member]

Debt Instrument [Line Items]

Loans payable

394,000

Debt instrument periodic payment

50,000

Amount owed as per agreement

344,000

Amount payble on complition eligible payment event

344,000

First Amendment Of Consulting [Member]

Debt Instrument [Line Items]

Prepay oncash retainer basis

5,000

Prepay oncash retainer basis

250

Prepay oncash retainer basis

$ 5,000

Second Amendment [Member]

Debt Instrument [Line Items]

Investment owned, face amount

$ 100,000

$ 200,000

Notes payable

$ 75,000

Percentage of royalty on net sales

4%

Second Amendment [Member] | Minimum [Member]

Debt Instrument [Line Items]

Notes payable

$ 10,000

Payment Settlement Agreement [Member] | Former Legal Counsel [Member]

Debt Instrument [Line Items]

Investment owned, face amount

$ 250,000

$ 2,608,914

Notes payable

$ 350,000

Accounts payable

2,608,914

Employment Agreement Termination And Separation Agreement [Member]

Debt Instrument [Line Items]

Notes payable

$ 789,267

Payment and Settlement Agreement [Member] | Convertible Notes Payable [Member] | University of California Innovation and Entrepreneurship [Member]

Debt Instrument [Line Items]

Notes payable

$ 175,000

$ 234,657

Agreed payment value

10,000

Accounts payable

$ 234,657

Payment of debt

$ 234,657

Sharp Settlement Agreement [Member]

Debt Instrument [Line Items]

Repayments of related party debt

$ 30,000

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Number of Shares, Warrants outstanding, Beginning balance	419,683,183	59,420,298	59,420,298
Weighted Average Exercise Price, Warrants outstanding, Beginning balance	$ 0.0074	$ 0.0718	$ 0.0718
Weighted Average Remaining Contractual Life, Warrants Outstanding	3 years 3 months 3 days	3 years 8 months 3 days	3 years 4 months 17 days	3 years 3 months 29 days
Number of Shares. Warrants Exercised	(74,100,000)
Weighted Average Exercise Price, Warrants Exercised	$ 0.0015
Number of Shares, Warrants Issued	83,333,333	187,927,001
Weighted Average Exercise Price, Warrants Issued		$ 0.0022
Weighted Average Remaining Contractual Life, Warrants Outstanding	4 years 7 months 24 days	3 years 8 months 26 days
Number of Shares, Warrants Expired	(33,401,307)
Weighted Average Exercise Price, Warrants Expired		$ (0.5121)
Number of Shares, Warrants outstanding, Ending balance	395,515,209	245,030,149	419,683,183	59,420,298
Weighted Average Exercise Price, Warrants outstanding, Ending balance	$ 0.0023	$ 0.0130	$ 0.0074	$ 0.0718
Number of Shares, Warrants Expired		(2,317,150)

Schedule of Exercise Prices of

Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable (Details) - $ / shares	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0011		$ 0.0088
Warrants, Outstanding (Shares)	395,515,209	419,683,183	245,030,149	59,420,298
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Outstanding and Exercisable (Shares)	395,515,209
Warrants, Outstanding (Shares)			245,030,149
Warrants, Exercisable (Shares)			245,030,149
Exercise Price Range One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0015		$ 0.0015
Warrants, Outstanding and Exercisable (Shares)	395,115,641
Warrants, Outstanding (Shares)			171,852,001
Warrants, Exercisable (Shares)			171,852,001
Exercise Price Range One [Member] | Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date	Mar. 31, 2026		Aug. 31, 2026
Exercise Price Range One [Member] | Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date	May 22, 2028		Apr. 14, 2027
Exercise Price Range Two [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.03890		$ 0.0100
Warrants, Outstanding and Exercisable (Shares)	208,227
Expiration Date	May 10, 2026
Warrants, Outstanding (Shares)			46,450,000
Warrants, Exercisable (Shares)			46,450,000
Exercise Price Range Two [Member] | Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date			Sep. 30, 2023
Exercise Price Range Two [Member] | Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date			Apr. 14, 2027
Exercise Price Range Three [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0470		$ 0.0200
Warrants, Outstanding and Exercisable (Shares)	172,341
Expiration Date	May 03, 2026		Sep. 30, 2023
Warrants, Outstanding (Shares)			927,273
Warrants, Exercisable (Shares)			927,273
Exercise Price Range Four [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 15		$ 0.03890
Warrants, Outstanding and Exercisable (Shares)	19,000
Expiration Date	Dec. 30, 2023		May 10, 2026
Warrants, Outstanding (Shares)			208,227
Warrants, Exercisable (Shares)			208,227
Exercise Price Range Five [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price			$ 0.0470
Expiration Date			May 03, 2026
Warrants, Outstanding (Shares)			172,341
Warrants, Exercisable (Shares)			172,341
Exercise Price Range Six [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price			$ 0.0700
Expiration Date			Sep. 30, 2023
Warrants, Outstanding (Shares)			25,377,426
Warrants, Exercisable (Shares)			25,377,426
Exercise Price Range Seven [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Outstanding (Shares)			42,881
Warrants, Exercisable (Shares)			42,881
Exercise Price Range Seven [Member] | Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price			$ 15
Expiration Date			Sep. 29, 2022
Exercise Price Range Seven [Member] | Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price			$ 15.7500
Expiration Date			Dec. 30, 2023

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Number of Shares, Options outstanding, Beginning balance	9,199,356
Weighted Average Exercise Price, Options outstanding, Beginning balance	$ 0.592
Weighted Average Remaining Contractual Life, Options outstanding	2 years 3 months	3 years 8 months 26 days
Number of Shares, Options Expired	(31,039)
Weighted Average Exercise Price, Options Expired	$ 11.200
Number of Shares, Options outstanding, Ending balance	9,168,317	9,199,356
Weighted Average Exercise Price, Options outstanding, Ending balance	$ 0.556

Schedule of Exercise Prices o_2

Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	9,168,317	9,201,032
Options Exercisable (Shares)	9,168,317	9,201,032
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price	$ 0.0190	$ 0.0190
Options Outstanding (Shares)	2,194,444	2,194,444
Options Exercisable (Shares)	2,194,444	2,194,444
Options, Expiration Date	Dec. 31, 2026	Dec. 31, 2026
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price	$ 0.0540	$ 0.0540
Options Outstanding (Shares)	1,700,000	1,700,000
Options Exercisable (Shares)	1,700,000	1,700,000
Options, Expiration Date	Sep. 30, 2025	Sep. 30, 2025
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price	$ 0.072	$ 0.072
Options Outstanding (Shares)	5,050,000	5,050,000
Options Exercisable (Shares)	5,050,000	5,050,000
Options, Expiration Date	Jul. 31, 2025	Jul. 31, 2025
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	223,873	256,588
Options Exercisable (Shares)	223,873	256,588
Exercise Price Range Four [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price	$ 7	$ 7
Options, Expiration Date	Nov. 21, 2023	Dec. 07, 2022
Exercise Price Range Four [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price	$ 159.25	$ 159.25
Options, Expiration Date	Dec. 09, 2027	Dec. 09, 2027

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - USD ($)							1 Months Ended	3 Months Ended		6 Months Ended			9 Months Ended
	Nov. 07, 2023	Oct. 01, 2023	Jun. 07, 2023	Apr. 12, 2023	Apr. 03, 2023	Apr. 03, 2023	Nov. 09, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2023	Sep. 26, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock shares authorised								5,000,000		5,000,000	5,000,000		5,000,000
Preferred stock value								$ 0.001		$ 0.001	$ 0.001		$ 0.001
Preferred stock value								$ 87,380	$ 138,050				$ 284,020	$ 400,307
Accrued dividends											$ 21,390
Preferred stock, shares undesignated								3,484,537		3,484,537	3,484,537		3,484,537		3,504,424
Common stock, shares authorized								2,000,000,000		2,000,000,000	2,000,000,000		2,000,000,000		2,000,000,000
Common stock par value								$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Common stock, shares outstanding								298,328,647		298,328,647	298,328,647		298,328,647		125,544,276
Common stock, conversion units shares													133,639,999
Exercise units								0	0				0	0
Common stock available for future issuances								630,558,175		630,558,175	630,558,175		630,558,175
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised													74,100,000
Exercise price of warrants								$ 0.0011	$ 0.0088	$ 0.0011	$ 0.0011		$ 0.0011	$ 0.0088
Weighted Average Remaining Contractual Life, Warrants Outstanding													4 years 7 months 24 days	3 years 8 months 26 days
Options Outstanding (Shares)								9,168,317	9,201,032	9,168,317	9,168,317		9,168,317	9,201,032
Options Exercisable (Shares)								9,168,317	9,201,032	9,168,317	9,168,317		9,168,317	9,201,032
Common stock, shares issued								298,328,647		298,328,647	298,328,647		298,328,647		125,544,276
Class of warrant or right outstanding not yet occurred								395,515,209		395,515,209	395,515,209		395,515,209
Exercise Price Range One [Member]
Class of Stock [Line Items]
Options Exercise Price													$ 0.0190	$ 0.0190
Options Outstanding (Shares)								2,194,444	2,194,444	2,194,444	2,194,444		2,194,444	2,194,444
Options Exercisable (Shares)								2,194,444	2,194,444	2,194,444	2,194,444		2,194,444	2,194,444
Options, Expiration Date													Dec. 31, 2026	Dec. 31, 2026
Exercise Price Range Two [Member]
Class of Stock [Line Items]
Options Exercise Price													$ 0.0540	$ 0.0540
Options Outstanding (Shares)								1,700,000	1,700,000	1,700,000	1,700,000		1,700,000	1,700,000
Options Exercisable (Shares)								1,700,000	1,700,000	1,700,000	1,700,000		1,700,000	1,700,000
Options, Expiration Date													Sep. 30, 2025	Sep. 30, 2025
Exercise Price Range Three [Member]
Class of Stock [Line Items]
Options Exercise Price													$ 0.072	$ 0.072
Options Outstanding (Shares)								5,050,000	5,050,000	5,050,000	5,050,000		5,050,000	5,050,000
Options Exercisable (Shares)								5,050,000	5,050,000	5,050,000	5,050,000		5,050,000	5,050,000
Options, Expiration Date													Jul. 31, 2025	Jul. 31, 2025
Exercise Price Range Four [Member]
Class of Stock [Line Items]
Options Outstanding (Shares)								223,873	256,588	223,873	223,873		223,873	256,588
Options Exercisable (Shares)								223,873	256,588	223,873	223,873		223,873	256,588
Exercise Price Range Four [Member] | Minimum [Member]
Class of Stock [Line Items]
Options Exercise Price													$ 7	$ 7
Options, Expiration Date													Nov. 21, 2023	Dec. 07, 2022
Exercise Price Range Four [Member] | Maximum [Member]
Class of Stock [Line Items]
Options Exercise Price													$ 159.25	$ 159.25
Options, Expiration Date													Dec. 09, 2027	Dec. 09, 2027
2014 Equity Plan [Member]
Class of Stock [Line Items]
Number of shares available for issuance			306,000,000
Share based compensation arrangement by share based payment award number of shares available for grant								6,325		6,325	6,325		6,325
Options to purchase shares													9,168,317
2015 Stock and Stock Option Plan [Member]
Class of Stock [Line Items]
Share based compensation arrangement by share based payment award number of shares available for grant								13,701,149		13,701,149	13,701,149		13,701,149
2015 Equity Plan [Member]
Class of Stock [Line Items]
Number of shares available for issuance													13,701,149
Subsequent Event [Member]
Class of Stock [Line Items]
Debt instrument, interest amount							$ 2,923
Conversion fees	$ 25,000
Conversion price							$ 0.0015
Debt conversion shares issuable							67,090,000
Convertible Notes [Member]
Class of Stock [Line Items]
Debt conversion shares issuable													652,721,529
In-The-Money Common Stock Warrants [Member]
Class of Stock [Line Items]
Warrants exercised								0	171,852,001	0	0		0	171,852,001
In-The-Money Common Stock Options [Member]
Class of Stock [Line Items]
Share price								$ 0.0011	$ 0.0088	$ 0.0011	$ 0.0011		$ 0.0011	$ 0.0088
Warrant [Member]
Class of Stock [Line Items]
Exercise units													39,144,372
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised													33,401,107
Warrant [Member] | Exercise Price Range One [Member]
Class of Stock [Line Items]
Exercise price of warrants								0.0015	0.0015	0.0015	0.0015		$ 0.0015	0.0015
Warrant [Member] | Exercise Price Range Two [Member]
Class of Stock [Line Items]
Exercise price of warrants								0.03890	0.0100	0.03890	0.03890		0.03890	0.0100
Warrant [Member] | Exercise Price Range Three [Member]
Class of Stock [Line Items]
Exercise price of warrants								0.0470	0.0200	0.0470	0.0470		0.0470	0.0200
Warrant [Member] | Exercise Price Range Four [Member]
Class of Stock [Line Items]
Exercise price of warrants								$ 15	$ 0.03890	$ 15	$ 15		$ 15	$ 0.03890
Common Stock [Member]
Class of Stock [Line Items]
Common stock available for future issuances								1,071,113,178		1,071,113,178	1,071,113,178		1,071,113,178
Warrant exercisable								0
Stock issued during period shares conversion of cash								39,144,372
Common Stock [Member] | Convertible Notes Three [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, conversion units shares		67,090,000
Debt instrument, Principal amount		$ 96,712
Debt instrument, interest amount		2,923
Conversion fees		1,000
Common stock, conversion units value		$ 100,635
Conversion price		$ 0.0015
Common Stock [Member] | In-The-Money Common Stock Warrants [Member]
Class of Stock [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number								31,039		31,039	31,039		31,039
Warrant exercisable								0		0	0		0
Warrants exercised								74,100,000		74,100,000	74,100,000		74,100,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorised								37,500		37,500	37,500		37,500		37,500
Preferred stock value								$ 0.001		$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock shares								37,500		37,500	37,500		37,500		37,500
Preferred stock liquidation preference value								$ 25,001		$ 25,001	$ 25,001		$ 25,001		$ 25,001
Preferred stock value								$ 21,703		$ 21,703	$ 21,703		$ 21,703		$ 21,703
Preferred stock shares								37,500		37,500	37,500		37,500		37,500
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion								1		1	1		1
Preferred stock liquidation preference value								$ 25,001		$ 25,001	$ 25,001		$ 25,001
Series B Preferred Stock [Member] | May 1991 Private Placement [Member]
Class of Stock [Line Items]
Preferred stock shares								37,500		37,500	37,500		37,500		37,500
Series H Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares available for issuance													1,376
Series I Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock value					$ 0.0015	$ 0.0015
Preferred stock shares								1,730		1,730	1,730		1,730
Preferred stock shares					3,500
Dividend rate					8%	8%
Preferred stock shares					$ 0.001	$ 0.001
Preferred stock value					$ 100	$ 100
Share price					$ 0.02	$ 0.02
License expense					$ 15,000,000	$ 15,000,000
Preferred stock value					15,000,000
Prepaid Royalties					$ 15,000,000	$ 15,000,000
Sale of stock, shares												1,700
Sale of stock, value												$ 170,000
Preferred stock, dividend paid in kind										$ 3,037
Shares additionally available for issuance								30		30	30		30
Share based compensation arrangement by share based payment award number of shares available for grant								1,770		1,770	1,770		1,770
Preferred stock shares				5,950				6,164		6,164	6,164	250	6,164
Series J Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock value				$ 0.006
Preferred stock shares				15,000
Dividend rate				8%
Preferred stock shares				$ 0.001
Preferred stock value				$ 100
License expense				20,000,000
Preferred stock value				20,000,000
Prepaid Royalties				20,000,000
Share based compensation arrangement by share based payment award number of shares available for grant								8,837		8,837	8,837		8,837
Compensated Absences Liability				$ 570,000
Number of shares issued								5,700		5,700	5,700		5,700
Number of shares issued								214		214	214		214

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	9 Months Ended
	Sep. 30, 2023 USD ($)
Aurora Capital LLC [Member]
Related Party Transaction [Line Items]
Services provided	$ 96,000

Summary of Current Cash Commitm

Summary of Current Cash Commitments in Employee Agreements (Details) - Forecast [Member]	12 Months Ended
	Sep. 30, 2024 USD ($)
Base Salary	$ 600,000
Benefits	61,200
Total	661,200
Dr Arnold S Lippa [Member]
Base Salary	300,000
Benefits	39,600
Total	339,600
Mr Margolis [Member]
Base Salary	300,000
Benefits	21,600
Total	$ 321,600

Summary of Principal Cash Oblig

Summary of Principal Cash Obligations and Commitments (Details)	Sep. 30, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	$ 751,385
2023	200,485
2024	505,900
2025	15,000
2026	15,000
2027	15,000
Licensing Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	90,185
2023	35,185
2024	10,000
2025	15,000
2026	15,000
2027	15,000
Employment Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	661,200	[1]
2023	165,300	[1]
2024	495,900	[1]
2025		[1]
2026		[1]
2027		[1]
[1]The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements.”

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)

9 Months Ended

12 Months Ended

Sep. 26, 2023

Aug. 03, 2023

Aug. 01, 2023

Jun. 07, 2023

Feb. 27, 2023

Dec. 31, 2021

Jun. 30, 2015

Jun. 27, 2014

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Dec. 31, 2021

Jul. 12, 2021

Other Commitments [Line Items]

Debt Instrument, Redemption, Description

The features and terms of the Phantom Stock are delineated in Phantom Stock Award Agreements (“Phantom Stock Award Agreements”) which describe that the shares of Phantom Stock that were awarded are non-forfeitable but unvested on the award date which was June 7, 2023 and vest as to the economic value of 50% of the shares of Phantom Stock awarded on the first event payment date (“First Event Payment Date”) and as to the economic value of 50% of the shares of Phantom Stock awarded on the second event payment date (“Second Event Payment Date”)

Fair market value, description

If the calculation of the payment based on the definition of Fair Market Value, exceeds 50% the amount of cash received by RespireRx with respect to a Payment Event, an initial payment shall be limited to 50% of the cash received by RespireRx with respect to the Payment Event and the unpaid balance shall be carried as a liability due to the Participant to be added to the payment amount of the Second Payment Event, subject to the same limitation

Purchase commitment, remaining minimum amount committed

$ 75,000

Accounts payable

$ 6,627,788

$ 5,724,390

Cash paid

$ 35,185

Patent fees

$ 30,185

Patent fees percent

50%

Annual maintenance fees

5,000

Accounts Payable And Accrued Expenses

$ 0

Commercial sale of product

350,000

Principal cash obligations and commitments

751,385

First Timed Payments [Member]

Other Commitments [Line Items]

Research and Development during period

150,000

Second Timed Payments [Member]

Other Commitments [Line Items]

Research and Development during period

$ 200,000

Three Installments [Member]

Other Commitments [Line Items]

Purchase commitment, remaining minimum amount committed

$ 25,000

Series I 8% Redeemable Preferred Stock [Member]

Other Commitments [Line Items]

Constitution of ordinary shares issued

250

Series J 8% Redeemable Preferred Stock [Member]

Other Commitments [Line Items]

Constitution of ordinary shares issued

250

Jeff Margolis [Member]

Other Commitments [Line Items]

Stock Issued During Period, Shares, Issued for Services

120,000,000

Arnold Lippa [Member]

Other Commitments [Line Items]

Stock Issued During Period, Shares, Issued for Services

70,000,000

Joseph R.Siegelbaum [Member]

Other Commitments [Line Items]

Stock Issued During Period, Shares, Issued for Services

20,000,000

Five Vendors [Member]

Other Commitments [Line Items]

Stock Issued During Period, Shares, Issued for Services

96,000,000

Margolis And Arnold Lippa [Member]

Other Commitments [Line Items]

Stock Issued During Period, Shares, Issued for Services

306,000,000

David Dickason [Member]

Other Commitments [Line Items]

Working hour rate per hours

$ 250

Settlement Agreement [Member]

Other Commitments [Line Items]

Loans payable

$ 394,000

Debt instrument periodic payment

50,000

Amount owed as per agreement

344,000

Amount payble on complition eligible payment event

344,000

First Amendment Of Consulting [Member]

Other Commitments [Line Items]

Prepay oncash retainer basis

5,000

Prepay oncash retainer basis

250

Prepay oncash retainer basis

$ 5,000

Services Agreement [Member]

Other Commitments [Line Items]

Deposit

$ 50,000

Share Transfer Agreement [Member]

Other Commitments [Line Items]

Ordinary shares issued

25,000,000

Original Principal Amount

$ 1

Stock Transfer Agreement [Member] | Common Stock [Member]

Other Commitments [Line Items]

Constitution of ordinary shares issued

25,000,000

Milwaukee Outreach Services Agreement [Member]

Other Commitments [Line Items]

Accounts payable

$ 50,000

University Of Illinois 2014 Exclusive License Agreement [Member]

Other Commitments [Line Items]

License fees

$ 25,000

Outstanding patent costs

$ 15,840

Percentage of royalty on net sale

4%

4%

Percentage of payment on sub licensee revenue

12.50%

Royalty expense

$ 100,000

100,000

Charge to operations with royalty obligation

0

$ 50,000

0

$ 100,000

University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Dosing of First Patient Phase Two Human Clinical Trial [Member]

Other Commitments [Line Items]

Payments for rent

10,000

University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Dosing of First Patient Phase Three Human Clinical Trial [Member]

Other Commitments [Line Items]

Payments for rent

150,000

University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After First New Drug Application Filing [Member]

Other Commitments [Line Items]

Payments for rent

500,000

University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Twelve Months of First Commercial Sale Member [Member]

Other Commitments [Line Items]

Payments for rent

1,000,000

2014 License Agreement [Member]

Other Commitments [Line Items]

Minimum annual royalty obligation

$ 100,000

2014 License Agreement [Member] | After First Year [Member]

Other Commitments [Line Items]

Commercial Product Sale

250,000

University Of Illinois 2014 Exclusive License Agreement Three [Member] | Due Within Five Days After Dosing of First Patient Phase Three Human Clinical Trial [Member]

Other Commitments [Line Items]

Payments for rent

$ 350,000

RespireRx [Member]

Other Commitments [Line Items]

Voting interest

50%

Phantom [Member]

Other Commitments [Line Items]

Payments aggregating

$ 25,000,000

Phantom [Member] | Phantom Stok Award Agreement [Member]

Other Commitments [Line Items]

Payments aggregating

$ 250,000

$ 500,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	2 Months Ended
	Nov. 07, 2023	Nov. 09, 2023	Sep. 30, 2023
Subsequent Event [Line Items]
Total Conversion price			$ 1,215,088
Unpaid patent and maintenance fees			35,185
Patent fees			$ 30,185
Percentage of patent fees			50%
Annual maintenance fees			$ 5,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Original Principal Amount		$ 96,712
Interest value		2,923
Fee amount		1,000
Total Conversion price		$ 100,635
Conversion shares of common stock		67,090,000
Conversion share price		$ 0.0015
Investment value	$ 25,000
Preferred stock investment	250